



Model List of Essential Medicines



BCG vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against tuberculosis](#)



Ebola vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against certain single viral diseases](#)



Japanese encephalitis vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against certain single viral diseases](#)



Medicines for COVID-19 [General information](#)

Section

Medicines for COVID-19

- Refer to WHO living guidelines

Indications

[COVID-19](#)



Abacavir [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 300 mg tablet (as sulfate)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Abacavir + dolutegravir + lamivudine [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid > tablet: 60 mg (as sulfate) + 5 mg + 30 mg (dispersible, scored)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Abacavir + lamivudine [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Abemaciclib [General information](#)

Section

Targeted therapies

Indications

Therapeutic equivalent to [palbociclib](#) for [Other specified malignant neoplasms of breast](#)

Abiraterone [General information](#)

Section

Hormones and antihormones

- Oral > Solid: 250 mg; 500 mg

Indications

[Malignant neoplasms of prostate](#)

Acamprosate calcium [General information](#)

Section

Medicines for alcohol use disorders

- Oral > Solid > tablet: 333 mg

Indications

[Disorders due to use of alcohol](#)

Acenocoumarol [General information](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [warfarin](#) for [Other specified diseases of arteries or arterioles](#) Therapeutic equivalent to [warfarin](#) for [Venous thromboembolism](#) Therapeutic equivalent to [warfarin](#) for [Cerebral ischaemic stroke due to embolic occlusion](#) Therapeutic equivalent to [warfarin](#) for [Atrial fibrillation](#)

Acetazolamide [General information](#)

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

- Oral > Solid: 250 mg

Indications

[Primary open-angle glaucoma](#)

Acetylcysteine [General information](#)

Section

Antidotes and other substances used in poisonings > Specific

- Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule
- Oral > Liquid: 10%; 20%

Indications

[Acute or subacute hepatic failure Exposure to or harmful effects of undetermined intent of analgesics, antipyretics](#)

[or nonsteroidal anti-inflammatory drugs](#)



Acetylsalicylic acid [General information](#)

Section

Medicines for acute migraine attacks

- Oral > Solid: 300 to 500 mg

Indications

[Migraine](#)

Section

Anti-platelet medicines

- Oral > Solid: 100 mg

Indications

[Acute myocardial infarction Cerebral ischaemic stroke](#)

Section

Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)

- Oral > Solid: 100 to 500 mg
- Local > Rectal > Suppository: 50 to 150 mg

Indications

[Pain](#)

Section

Medicines for juvenile joint diseases

- Local > Rectal > Suppository: 150 mg; 300 mg
- Oral > Solid > dispersible tablet: 75 mg; 300 mg; 500 mg
- Oral > Solid > tablet: 75 to 500 mg

Indications

[Acute rheumatic fever without mention of heart involvement Mucocutaneous lymph node syndrome Juvenile idiopathic arthritis](#)



Acetylsalicylic acid + atorvastatin + ramipril [General information](#)

Section

Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease

- Oral > Solid > tablet: 100 mg + 20 mg + 2.5 mg; 100 mg + 20 mg + 5 mg; 100 mg + 20 mg + 10 mg; 100 mg + 40 mg + 2.5 mg; 100 mg + 40 mg + 5 mg; 100 mg + 40 mg + 10 mg

Indications

[Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke](#)



Acetylsalicylic acid + simvastatin + ramipril + atenolol + hydrochlorothiazide [General information](#)

Section

Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease

- Oral > Solid > tablet: 100 mg + 20 mg + 5 mg + 50 mg + 12.5 mg

Indications

[Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke](#)



Aciclovir [General information](#)

Section

Ophthalmological preparations > Anti-infective agents

- Local > Ophthalmological > Ointment: 3% w/w

Indications

[Herpes simplex keratitis](#)

Section

Antiherpes medicines

- Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)
- Oral > Liquid: 200 mg per 5 mL
- Oral > Solid: 200 mg tablet
- Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)

Indications

[Herpes simplex infections Zoster Varicella](#)

Section

Medicines for viral central nervous system infections

- Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)
- Oral > Liquid: 200 mg per 5 mL
- Oral > Solid: 200 mg tablet

- Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)

Indications

[Herpes simplex infections Zoster Varicella](#)



Aclidinium [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [tiotropium bromide](#) for [Chronic obstructive pulmonary disease](#)



Activated charcoal [General information](#)

Section

Antidotes and other substances used in poisonings > Non-specific

- Oral > Liquid: 50 mg granules for oral suspension

Indications

[Unspecified injury, poisoning or certain other consequences of external causes](#)



Adalimumab [General information](#)

Section

Immunomodulators for non-malignant disease

- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

[Axial spondyloarthritis Crohn disease site Rheumatoid arthritis](#)

Section

Medicines for juvenile joint diseases

- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

[Juvenile idiopathic arthritis](#)

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Parenteral > General injections > SC: 10 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.; 80 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.

Indications

[Psoriasis of unspecified type](#)



Afatinib [General information](#)

Section

Targeted therapies

Indications

Therapeutic equivalent to [erlotinib](#) for [Other specified malignant neoplasms of bronchus or lung](#)



Albendazole [General information](#)

Section

Intestinal anthelmintics

- Oral > Solid > tablet: 400 mg (chewable, scored)

Indications

[Trichuriasis Echinococcosis Cysticercosis Enterobiasis Hookworm diseases Ascariasis](#)

Section

Cysticidal medicines

- Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)

Indications

[Other specified echinococcosis Cysticercosis of central nervous system](#)

Section

Antifilarials

- Oral > Solid > tablet: 400 mg (chewable, scored)

Indications

[Lymphatic filariasis](#)



Alcohol based hand rub [General information](#)

Section

Disinfectants

- Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol

Indications

[Denatured alcohol](#)

Alcuronium [General information](#)

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

- Parenteral > General injections > IV: 5 mg per mL in 2 mL ampoule (alcuronium chloride)

Indications

[Muscle relaxants](#)

Alfacalcidol [General information](#)

Section

Medicines for endocrine disorders

- Oral > Liquid: 2 µg per mL
- Oral > Solid > capsule: 0.25 µg; 1 µg

Indications

[Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport](#)

All-trans retinoic acid [General information](#)

Section

Targeted therapies

- Oral > Solid: 10 mg capsule

Indications

[Acute myeloid leukaemia with recurrent genetic abnormalities](#)

Allopurinol [General information](#)

Section

Medicines used to treat gout

- Oral > Solid: 100 mg

Indications

[Gout](#)

Alteplase [General information](#)

Section

Thrombolytic medicines

- Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection

Indications

[Cerebral ischaemic stroke](#)

Amidotrizoate [General information](#)

Section

Diagnostic agents > Radiocontrast media

- Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)

Indications

[Amidotrizoate](#)

Amikacin [General information](#)

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to [gentamicin](#) for [Other specified conjunctivitis](#) Therapeutic equivalent to [gentamicin](#) for [Infectious blepharitis](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Indications

First choice

[Neutropenia \(high-risk\)](#) co-prescribed with [cefotaxime Inflammatory and other diseases of prostate \(severe\)](#) co-prescribed with [cefotaxime Acute pyelonephritis \(severe\)](#) co-prescribed with [ceftriaxone Inflammatory and other diseases of prostate \(severe\)](#) co-prescribed with [ceftriaxone Acute pyelonephritis \(severe\)](#)

Section

Antituberculosis medicines

- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Amloride [General information](#)

Section

Diuretics

- Oral > Solid: 5 mg (hydrochloride)

Indications

[Oedema Ascites](#)



Amiodarone [General information](#)

Section

Antiarrhythmic medicines

- Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)
- Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)

Indications

[Cardiac arrhythmia](#)



Amitriptyline [General information](#)

Section

Medicines for depressive disorders

- Oral > Solid: 25 mg; 75 mg

Indications

[Depressive disorders](#)

Section

Medicines for migraine prophylaxis

- Oral > Solid > tablet: 25 mg

Indications

[Migraine](#)

Section

Medicines for other common symptoms in palliative care

- Oral > Liquid: 25 mg per 5 mL
- Oral > Solid > tablet: 25 mg; 10 mg; 75 mg

Indications

[Palliative care](#)



Amlodipine [General information](#)

Section

Antihypertensive medicines

- Oral > Solid: 5 mg (as maleate, mesylate or besylate)

Indications

[Essential hypertension](#)



Amodiaquine [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)

Indications



Amoxicillin [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
- Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
- Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)

Indications

First choice

[Acute pharyngitis](#) [Periapical abscess without sinus](#) [Acute sinusitis](#) [Acute otitis media](#) [Chronic obstructive pulmonary disease with acute exacerbation](#) [Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [children]

Second choice

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#) [Infectious cystitis](#)

Section

Medicines for bacterial central nervous system infections

- Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
- Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
- Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)

Indications

Second choice

[Bacterial meningitis](#)



Amoxicillin + clavulanic acid [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
- Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

First choice

[Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [children] [Infectious cystitis](#) [Acute sinusitis](#) [Neutropenia \(low-risk\)](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#) [Bacterial cellulitis, erysipelas or lymphangitis](#) [Chronic obstructive pulmonary disease with acute exacerbation](#) [Peritonitis \(mild-moderate\)](#) [Peritoneal abscess \(mild-moderate\)](#)

Second choice

[Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [Osteomyelitis or osteitis](#) [Bacterial infection of joint](#) [Other specified prophylactic measures](#) [Acute otitis media](#)

Other indications

[Bacterial infection of unspecified site](#)

Section

Antituberculosis medicines

- Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Amphotericin B [General information](#)

Section

Antifungal medicines

- Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)

Indications

[Candidosis](#) [Blastomycosis](#) [Cryptococcosis](#) [Coccidioidomycosis](#) [Histoplasmosis](#) [Sporotrichosis](#) [Aspergillosis](#)

Section

Antileishmaniasis medicines

- Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)

Indications

[Visceral leishmaniasis](#)



Ampicillin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
- Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

Second choice

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Section

Medicines for bacterial central nervous system infections

- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection

Indications

Second choice

[Bacterial meningitis](#)



Anakinra [General information](#)

Section

Medicines for juvenile joint diseases

- Parenteral > General injections > SC: 100 mg per 0.67 mL in pre-filled syringe

Indications

[Juvenile systemic arthritis](#)



Anastrozole [General information](#)

Section

Hormones and antihormones

- Oral > Solid: 1 mg tablet

Indications

[Other specified malignant neoplasms of breast](#) [Malignant neoplasms of breast](#)



Anidulafungin [General information](#)

Section

Antifungal medicines

Indications

Therapeutic equivalent to [micafungin](#) for [Systemic or invasive candidosis](#)

Ansuvimab [General information](#)

Section

Medicines for Ebola virus disease

- Parenteral > General injections > IV: 400 mg powder for injection

Indications

[Ebola virus disease](#)

Anti-D immunoglobulin [General information](#)

Section

Human immunoglobulins

- Parenteral > General injections > IV: 250 µg in single-dose vial
- Parenteral > General injections > IM: 250 µg in single-dose vial

Indications

[Maternal care for red cell antibodies Rh incompatibility reaction](#)

Anti-rabies immunoglobulin [General information](#)

Section

Human immunoglobulins

- Parenteral > General injections > IM: 150 IU per mL in vial
- Parenteral > Locoregional injections > Other: 150 IU per mL in vial

Indications

[Rabies](#)

Anti-rabies virus monoclonal antibodies [General information](#)

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

- Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)

Indications

[Rabies](#)

Anti-tetanus immunoglobulin [General information](#)

Section

Human immunoglobulins

- Parenteral > General injections > IM: 500 IU in vial

Indications

[Tetanus](#)

Antirabies hyperimmune serum [General information](#)

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

- Parenteral > General injections > unspecified: 1000 IU in 5 mL ampoule

Indications

[Rabies](#)

Antivenom immunoglobulin [General information](#)

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

- Parenteral > General injections > IV:

Indications

[Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified](#)

Antivenom sera [General information](#)

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

- Parenteral > General injections > IV:

Indications

[Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified](#)

Apixaban [General information](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) for [Other specified atrial fibrillation](#) Therapeutic equivalent to [dabigatran](#) for [Venous thromboembolism](#)

Aprepitant [General information](#)

Section

Antiemetic medicines

- Oral > Liquid: 125 mg powder for oral suspension (in sachet)
- Oral > Solid > capsule: 80 mg; 125 mg; 165 mg

Indications

[Nausea or vomiting](#)

Aripiprazole [General information](#)

Section

Medicines for psychotic disorders

- Parenteral > General injections > IM: 300 mg powder and solvent for suspension; 400 mg powder and solvent for suspension

Indications

Therapeutic equivalent to [risperidone](#) for [Schizophrenia or other primary psychotic disorders](#) Therapeutic equivalent to [paliperidone](#) for [Schizophrenia or other primary psychotic disorders](#)

Arpraziquantel [General information](#)

Section

Antischistosomal and other antitrepatode medicines

- Oral > Solid > dispersible tablet: 150 mg

Indications

Therapeutic equivalent to [praziquantel](#) for [Schistosomiasis](#)

Arsenic trioxide [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion

Indications

[Acute myeloid leukaemia with recurrent genetic abnormalities](#)

Artemether [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Parenteral > General injections > IM: 20 mg per mL in 1 mL ampoule (oily injection); 40 mg per mL in 1 mL ampoule (oily injection)

Indications

[Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax](#)

Artemether + lumefantrine [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > dispersible tablet: 20 mg + 120 mg

- Oral > Solid > tablet: 20 mg + 120 mg

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)



Artesunate [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Parenteral > General injections > IV: 60 mg in vial powder for injection; 30 mg in vial powder for injection; 120 mg in vial powder for injection
- Local > Rectal > Other: 100 mg capsules

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)



Artesunate + amodiaquine [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg
- Oral > Solid > tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg tablet

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)



Artesunate + mefloquine [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > tablet: 25 mg + 50 mg (as hydrochloride); 100 mg + 200 mg (as hydrochloride)

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)



Artesunate + pyronaridine [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > tablet: 60 mg + 180 mg (tetraphosphate)
- Oral > Solid > granules: 20 mg + 60 mg (tetraphosphate)

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)



Artesunate - sulfadoxine + pyrimethamine [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > tablet: 50 mg [3] + 500 mg + 25 mg [1] in copackage (scored)

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)



Ascorbic acid [General information](#)

Section

Vitamins and minerals

- Oral > Solid: 50 mg

Indications

[Scurvy](#)



Asparaginase [General information](#)

Section

Cytotoxic medicines

- Powder for injection: 10 000 IU in vial.
- Parenteral > General injections > unspecified: 10000 IU in vial powder for injection

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Lymphoid leukaemia, not elsewhere classified](#)



Atazanavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Atazanavir + ritonavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Atenolol [General information](#)

Section

Antianginal medicines

- Oral > Solid: 50 mg; 100 mg

Indications

[Angina pectoris](#)

Section

Antihypertensive medicines

- Oral > Solid: 50 mg; 100 mg

Indications

[Essential hypertension](#) Therapeutic equivalent to [bisoprolol](#) for [Essential hypertension](#)



Atezolizumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion
- Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion

Indications

[Other specified malignant neoplasms of bronchus or lung](#) Therapeutic equivalent to [pembrolizumab](#) for [Other specified malignant neoplasms of bronchus or lung](#) Therapeutic equivalent to [pembrolizumab](#) for [Adenocarcinoma of stomach Hepatocellular carcinoma of liver](#)



Atoltivimab + maftivimab + odesivimab [General information](#)

Section

Medicines for Ebola virus disease

- Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial

Indications

[Ebola virus disease](#)



Atorvastatin [General information](#)

Section

Lipid-lowering agents

Indications

Therapeutic equivalent to [simvastatin](#) for [Mixed hyperlipidaemia](#) Therapeutic equivalent to [simvastatin](#) for [Coronary atherosclerosis](#)



Atorvastatin + perindopril + amlodipine [General information](#)

Section

Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease

- Oral > Solid > tablet: 20 mg + 5 mg + 5 mg; 20 mg + 10 mg + 10 mg; 40 mg + 5 mg + 5 mg; 40 mg + 10 mg + 10 mg

Indications

[Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke](#)

Atracurium [General information](#)

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

- Parenteral > General injections > IV: 10 mg per mL (besylate)

Indications

[Muscle relaxants](#) Therapeutic equivalent to [vecuronium](#) for [Muscle relaxants](#)

Atropine [General information](#)

Section

Diagnostic agents > Ophthalmic medicines

Indications

Therapeutic equivalent to [tropicamide](#) for [Cycloplegic drug](#)

Section

Ophthalmological preparations > Mydriatics

- Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)

Indications

[Anterior uveitis](#)

Section

Preoperative medication and sedation for short-term procedures

- Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule or vial (sulfate); 400 µg per mL in 1 mL ampoule or vial (sulfate)

Indications

[Parasympatholytics \[anticholinergics and antimuscarinics\] and spasmolytics](#)

Section

Antidotes and other substances used in poisonings > Specific

- Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule or vial (sulfate)

Indications

[Exposure to or harmful effects of undetermined intent of pesticides](#)

Axicabtagene ciloleucel [General information](#)

Section

Antineoplastics and supportive medicines

- Cell suspension for infusion: 2×10^6 anti-CD19 CAR-positive viable T-cells per kg of body weight.

Indications

[Diffuse large B-cell lymphomas](#)

Axitinib [General information](#)

Section

Targeted therapies

- Oral > Solid > tablet: 1 mg; 3 mg; 5 mg

Indications

[Renal cell carcinoma of kidney, except renal pelvis](#)

Azacitidine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 100 mg in vial powder for injection

Indications

[Myeloid leukaemia](#)

Azathioprine [General information](#)

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

- Oral > Solid > tablet: 50 mg (scored)

Indications

[Rheumatoid arthritis, serology unspecified Psoriatic arthritis](#)

Section

Immunomodulators for non-malignant disease

- Oral > Solid > tablet: 50 mg (scored)
- Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial

- powder for injection (as sodium salt)
- Oral > Liquid: 10 mg per mL
- Oral > Solid > tablet: 25 mg; 50 mg (scored)

Indications

[Relapsing-remitting multiple sclerosis](#) [Failure or rejection of transplanted organs or tissues](#)



Azithromycin [General information](#)

Section

Ophthalmological preparations > Anti-infective agents

- Local > Ophthalmological > Solution (eye drops): 1.5% eye drops

Indications

[Trachoma](#)

Section

Watch group antibiotics

- Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

First choice

[Trachoma](#) [Cholera](#) [Cholera \[children\]](#) [Paratyphoid fever](#) [Chlamydia trachomatis](#) [Typhoid fever](#) [Yaws](#) co-prescribed with [ceftriaxone](#) [Gonococcal infection](#)

Second choice

[Infectious gastroenteritis or colitis without specification of infectious agent](#) co-prescribed with [cefixime](#) [Gonococcal infection](#)



Aztreonam [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

[Other specified bacterial diseases](#)



Baclofen [General information](#)

Section

Medicines for cerebral palsy

- Oral > Liquid: 10 mg per 5 mL
- Parenteral > Locoregional injections > Intrathecal: 500 µg per mL in ampoule
- Oral > Solid > tablet: 10 mg

Indications

[Spastic cerebral palsy](#)



Barium sulfate [General information](#)

Section

Diagnostic agents > Radiocontrast media

- Oral > Liquid: Aqueous suspension

Indications

[Barium sulfate with suspending agents](#)



Beclometasone [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

- Respiratory > Inhalation > aerosol: 50 µg per dose (dipropionate); 250 µg per dose (dipropionatae)

Indications

[Asthma](#) Therapeutic equivalent to [budesonide](#) for [Asthma](#)



Beclometasone + formoterol [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [budesonide + formoterol](#) for [Asthma](#)

Bedaquiline [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > tablet: 100 mg tablet; 20 mg tablet

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Beinaglutide [General information](#)

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for [Obesity](#)

Bendamustine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL

Indications

[Chronic lymphocytic leukaemia or small lymphocytic lymphoma Follicular lymphoma](#)

Benzathine benzylpenicillin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > IM: 1.2 million IU in vial (\approx 900 mg) powder for injection; 2.4 million IU in vial (\approx 1.8 g) powder for injection

Indications

First choice

[Syphilis](#)

Other indications

[Bacterial infection of unspecified site](#)

Benznidazole [General information](#)

Section

American trypanosomiasis

- Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg

Indications

[Chagas disease](#)

Benzoic acid + salicylic acid [General information](#)

Section

Dermatological medicines > Antifungal medicines

- Local > Topical > Cream: 6% + 3%
- Local > Topical > Ointment: 6% + 3%

Indications

[Fungal infection of the skin](#)

Benzoyl peroxide [General information](#)

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Local > Topical > Cream: 5%
- Local > Topical > Lotion: 5%

Indications

[Acne](#)



Benzyl benzoate [General information](#)

Section

Dermatological medicines > Scabicides and pediculicides

- Local > Topical > Lotion: 25%

Indications

[Pediculosis corporis](#) [Pediculosis capitis](#) [Scabies](#) [Pthiriasis](#)



Benzylpenicillin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)

Indications

First choice

[Syphilis](#)

Second choice

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Section

Medicines for bacterial central nervous system infections

- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)

Indications

Second choice

[Bacterial meningitis](#)



Betamethasone [General information](#)

Section

Dermatological medicines > Anti-inflammatory and antipruritic medicines

- Local > Topical > Cream: 0.1% (as valerate)
- Local > Topical > Ointment: 0.1% (as valerate)

Indications

[Dermatitis or eczema](#) [Pruritus due to skin disorder](#) [Psoriasis of unspecified type](#) [Lichen planus](#)



Bevacizumab [General information](#)

Section

Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

- Parenteral > Locoregional injections > Intravitreal: 25 mg per mL

Indications

[Age related macular degeneration](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion

Indications

[Hepatocellular carcinoma of liver](#)



Bicalutamide [General information](#)

Section

Hormones and antihormones

- Oral > Solid: 50 mg

Indications

[Malignant neoplasms of prostate](#)

Binimetinib [General information](#)

Section

Targeted therapies

Indications

Therapeutic equivalent to [trametinib](#) for [Other specified melanoma of skin](#)

Biperiden [General information](#)

Section

Medicines for parkinsonism

- Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)
- Oral > Solid: 2 mg tablet (hydrochloride)

Indications

[Parkinson disease](#)

Bisacodyl [General information](#)

Section

Laxatives

Indications

Therapeutic equivalent to [senna](#) for [Constipation](#)

Bisoprolol [General information](#)

Section

Medicines used in heart failure

- Oral > Solid: 1.25 mg; 5 mg

Indications

[Heart failure](#)

Section

Antianginal medicines

- Oral > Solid: 1.25 mg; 5 mg

Indications

[Angina pectoris](#)

Section

Antihypertensive medicines

- Oral > Solid: 1.25 mg; 5 mg

Indications

[Essential hypertension](#)

Section

Antiarrhythmic medicines

- Oral > Solid: 1.25 mg; 5 mg

Indications

[Cardiac arrhythmia](#)

Section

Medicines for migraine prophylaxis

- Oral > Solid: 1.25 mg; 5 mg

Indications

[Migraine](#)

Bleomycin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)

Indications

[Other specified malignant neoplasms of the ovary](#) [Germ cell tumour of testis](#) [Kaposi sarcoma of unspecified primary site](#) [Hodgkin lymphoma](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Blinatumomab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial

Indications

[B lymphoblastic leukaemia or lymphoma, not elsewhere classified](#)

Bortezomib [General information](#)

Section

Targeted therapies

- Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection

Indications

[Plasma cell myeloma](#)

Brexpiprazole [General information](#)

Section

Medicines for depressive disorders

- Oral > Solid > tablet: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg

Indications

[Depressive disorders](#)

Bromocriptine [General information](#)

Section

Medicines for central nervous system disorders

- Oral > Solid: 2.5 mg; 5 mg

Indications

[Parkinson disease](#)

Section

Medicines for disorders of the pituitary hormone system

Indications

Therapeutic equivalent to [cabergoline](#) for [Other specified benign neoplasm of endocrine glands](#)

Budesonide [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

- Respiratory > Inhalation > powder: 100 µg per actuation in dry powder inhaler; 200 µg per actuation in dry powder inhaler
- Respiratory > Inhalation > suspension: 100 µg per actuation in pressurized metered dose inhaler; 200 µg per actuation in pressurized metered dose inhaler

Indications

[Asthma](#)

Budesonide + formoterol [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

- Respiratory > Inhalation > powder: 100 µg + 6 µg per dose actuation in dry powder inhaler; 200 µg + 6 µg per dose actuation in dry powder inhaler

Indications

[Asthma](#)

Budesonide + salmeterol [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [budesonide + formoterol](#) for [Asthma](#)

Bumetanide [General information](#)

Section

Medicines used in heart failure

Indications

Therapeutic equivalent to [furosemide](#) for [Heart failure](#)

Section

Diuretics

Indications

Therapeutic equivalent to [furosemide](#) for [Anuria or oliguria](#) Therapeutic equivalent to [furosemide](#) for [Oedema](#)

Bupivacaine [General information](#)

Section

Local anaesthetics

- Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 8% glucose solution
- Parenteral > General injections > unspecified: 0.25% (hydrochloride); 0.5% (hydrochloride)

Indications

[Local anaesthetics](#)

Buprenorphine [General information](#)

Section

Medicines for opioid use disorders

Indications

Therapeutic equivalent to [methadone](#) for [Opioid dependence](#)

Bupropion [General information](#)

Section

Medicines for nicotine use disorders

- Oral > Solid: 150 mg sustained-release (hydrochloride)

Indications

[Nicotine dependence](#)

C1 esterase inhibitor [General information](#)

Section

Human immunoglobulins

- Parenteral > General injections > IV: 500 IU in vial powder for injection

Indications

[Hereditary angioedema](#)

Cabergoline [General information](#)

Section

Medicines for disorders of the pituitary hormone system

- Oral > Solid > tablet: 0.5 mg; 1 mg

Indications

[Other specified benign neoplasm of endocrine glands](#)

Section

Medicines for central nervous system disorders

- Oral > Solid > tablet: 0.5 mg

Indications

[Parkinson disease](#)

Calamine [General information](#)

Section

Dermatological medicines > Anti-inflammatory and antipruritic medicines

- Local > Topical > Lotion:

Indications

[Pruritus](#)

Calcipotriol [General information](#)

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Local > Topical > Cream: 50 µg per mL (0.005%)
- Local > Topical > Lotion: 50 µg per mL (0.005%)
- Local > Topical > Ointment: 50 µg per mL (0.005%)

Indications

[Psoriasis of unspecified type](#)



Calcitriol [General information](#)

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to [calcipotriol](#) for [Psoriasis of unspecified type](#)

Section

Medicines for endocrine disorders

- Oral > Solid > capsule: 0.25 µg; 0.5 µg

Indications

[Chronic kidney disease, stage unspecified](#) [Disorders of vitamin D metabolism or transport](#)



Calcium [General information](#)

Section

Vitamins and minerals

- Oral > Solid: 500 mg (elemental calcium)

Indications

[Calcium deficiency](#)



Calcium folinate (leucovorin calcium) [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 15 mg tablet
- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule
- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- Oral > Solid > tablet: 15 mg; 5 mg; 25 mg

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Malignant neoplasm metastasis in large intestine](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Malignant trophoblastic neoplasms of placenta](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Malignant neoplasms of rectum](#) [Malignant neoplasms of colon](#)



Calcium gluconate [General information](#)

Section

Vitamins and minerals

- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Indications

[Tetany due to acute calcium deficiency](#)

Section

Antidotes and other substances used in poisonings > Specific

- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule or vial (10%)

Indications

[Hypermagnesaemia](#)



Canagliflozin [General information](#)

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [empagliflozin](#) for [Type 2 diabetes mellitus](#)



Capecitabine [General information](#)

Section

Cytotoxic medicines

- Oral > Solid > tablet: 150 mg; 500 mg

Indications

[Other specified malignant neoplasms of breast](#) [Malignant neoplasm metastasis in large intestine](#) [Malignant neoplasms of rectum](#) [Malignant neoplasms of colon](#)



Capreomycin [General information](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Captopril [General information](#)

Section

Medicines used in heart failure

- Oral > Solid: 25 mg

Indications

[Heart failure](#)



Carbachol [General information](#)

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

Indications

Therapeutic equivalent to [pilocarpine](#) for [Acute angle closure with pupillary block](#) Therapeutic equivalent to [pilocarpine](#) for [Ocular hypertension](#) Therapeutic equivalent to [pilocarpine](#) for [Primary open-angle glaucoma](#)



Carbamazepine [General information](#)

Section

Medicines for bipolar disorders

- Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg

Indications

[Bipolar or related disorders](#)

Section

Antiseizure medicines

- Oral > Liquid: 100 mg per 5 mL
- Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)

Indications

[Epilepsy or seizures](#)

Section

Medicines for neurological disorders

- Oral > Liquid: 100 mg per 5 mL
- Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)
- Oral > Solid > capsule: 100 mg (extended-release); 200 mg (extended-release); 300 mg (extended-release)

Indications

[Trigeminal neuralgia](#)



Carbetocin [General information](#)

Section

Uterotonics

- Parenteral > General injections > IV: 100 µg per mL (heat stable)

Indications

[Postpartum haemorrhage](#)



Carbimazole [General information](#)

Section

Thyroid hormones and antithyroid medicines

Indications

Therapeutic equivalent to [methimazole](#) for [Thyrotoxicosis](#)



Carboplatin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60

mL

Indications

[Other specified malignant neoplasms of bronchus or lung](#) [Other specified gliomas of brain](#) [Malignant neoplasms of nasopharynx](#) [Malignant neoplasms of breast](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Other specified carcinomas of ovary](#) [Retinoblastoma](#) [Other specified malignant neoplasms of the ovary](#) [Germ cell tumour of testis](#) [Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Malignant neoplasms of cervix uteri](#) [Malignant neoplasms of hypopharynx](#) [Malignant neoplasms of nasopharynx](#) [Malignant neoplasms of oropharynx](#)

Carmellose [General information](#)

Section

Ophthalmological preparations

Indications

Therapeutic equivalent to [hypromellose](#) for [Keratoconjunctivitis sicca](#)

Carvedilol [General information](#)

Section

Medicines used in heart failure

Indications

Therapeutic equivalent to [bisoprolol](#) for [Heart failure](#)

Section

Antianginal medicines

Indications

Therapeutic equivalent to [bisoprolol](#) for [Angina pectoris](#)

Section

Antihypertensive medicines

Indications

Therapeutic equivalent to [bisoprolol](#) for [Essential hypertension](#)

Section

Antiarrhythmic medicines

Indications

Therapeutic equivalent to [bisoprolol](#) for [Cardiac arrhythmia](#)

Caspofungin [General information](#)

Section

Antifungal medicines

Indications

Therapeutic equivalent to [micafungin](#) for [Systemic or invasive candidosis](#)

Cefalexin [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid: 250 mg (as monohydrate)
- Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
- Oral > Solid > dispersible tablet: 125 mg; 250 mg

Indications

First choice

[Bacterial cellulitis, erysipelas or lymphangitis](#)

Second choice

[Chronic obstructive pulmonary disease with acute exacerbation](#) [Acute pharyngitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Cefazolin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection

Indications

First choice

[Other specified prophylactic measures](#) [Other specified prophylactic measures](#)

Second choice

[Bacterial infection of joint Osteomyelitis or osteitis](#)

Other indications

[Surgical site infection](#)

Cefepime [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection

Indications

[Other specified bacterial diseases](#)

Cefiderocol [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)

Cefixime [General information](#)

Section

Watch group antibiotics

- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)

Indications

Second choice

[Infectious gastroenteritis or colitis without specification of infectious agent](#) [Gonococcal infection](#)

Cefotaxime [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

[Bacterial meningitis](#) [Inflammatory and other diseases of prostate \(severe\)](#) [Acute pyelonephritis \(severe\)](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) [Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) [Peritoneal abscess \(mild-moderate\)](#) [Peritoneal abscess \(severe\)](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#) [Peritonitis \(mild-moderate\)](#) [Peritonitis \(severe\)](#)

Second choice

[Inflammatory and other diseases of prostate \(mild to moderate\)](#) [Acute pyelonephritis \(mild to moderate\)](#) [Bacterial infection of joint Osteomyelitis or osteitis](#)

Section

Medicines for bacterial central nervous system infections

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

[Bacterial meningitis](#)

Ceftaroline [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection

Indications

[Other specified bacterial diseases](#)

Ceftazidime [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

Indications

First choice

[Endophthalmitis](#)

Other indications

[Pseudomonas aeruginosa resistant to other antibiotic](#)

Ceftazidime + avibactam [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales](#)

Ceftolozane + tazobactam [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g + 0.5 g powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#)

Ceftriaxone [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

[Other specified pneumonia \(Hospital-acquired pneumonia\) Inflammatory and other diseases of prostate \(severe\) Bacterial meningitis Acute pyelonephritis \(severe\) Paratyphoid fever Gonococcal infection Typhoid fever Peritonitis \(mild-moderate\) Peritonitis \(severe\) Peritoneal abscess \(mild-moderate\) Peritoneal abscess \(severe\) Endophthalmitis Bacterial pneumonia \(Community-acquired pneumonia - severe\) Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\] co-prescribed with metronidazole Necrotising fasciitis](#)

Second choice

[Inflammatory and other diseases of prostate \(mild to moderate\)](#) [Acute pyelonephritis \(mild to moderate\)](#) [Bacterial infection of joint Osteomyelitis or osteitis](#) [Infectious gastroenteritis or colitis without specification of infectious agent](#)

Other indications

[Bacterial infection of unspecified site](#)

Section

Medicines for bacterial central nervous system infections

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

[Bacterial meningitis](#)

Cefuroxime [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

Indications

Second choice

[Other specified prophylactic measures](#)

Cemiplimab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion

Indications

Therapeutic equivalent to [pembrolizumab](#) for [Other specified malignant neoplasms of bronchus or lung](#)

Therapeutic equivalent to [pembrolizumab](#) for [Adenocarcinoma of stomach](#) [Other specified malignant neoplasms of bronchus or lung](#)

Certolizumab pegol [General information](#)

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for [Axial spondyloarthritis](#) Therapeutic equivalent to [adalimumab](#) for [Crohn disease site](#) Therapeutic equivalent to [adalimumab](#) for [Rheumatoid arthritis](#)

Section

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab](#) for [Juvenile idiopathic arthritis](#)

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to [adalimumab](#) for [Psoriasis of unspecified type](#)

Cetirizine [General information](#)

Section

Antiallergics and medicines used in anaphylaxis

Indications

Therapeutic equivalent to [loratadine](#) for [Allergic or hypersensitivity conditions of unspecified type](#)

Chlorambucil [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 2 mg tablet

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#)



Chloramphenicol [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
- Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
- Oral > Liquid: 150 mg per 5 mL (as palmitate)
- Oral > Solid: 250 mg capsule

Indications

Second choice

[Bacterial meningitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Section

Medicines for bacterial central nervous system infections

- Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
- Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection

Indications

Second choice

[Bacterial meningitis](#)



Chlorhexidine [General information](#)

Section

Antiseptics

- Local > Topical > Solution: 5% (digluconate) for dilution

Indications

[Chlorhexidine](#)



Chlorine base compound [General information](#)

Section

Disinfectants

- Local > Topical > Powder: 0.1% available chlorine for solution
- Local > Topical > Liquid: 0.1% available chlorine for solution
- Local > Topical > Solid: 0.1% available chlorine for solution

Indications

[Disinfectant, not elsewhere classified](#)



Chloroquine [General information](#)

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
- Oral > Solid: 150 mg tablet (as phosphate or sulfate)

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium ovale](#) [Malaria due to Plasmodium malariae](#)

[Malaria due to Plasmodium vivax](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)
- Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
- Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)
- Oral > Liquid: 50 mg per 5 mL (base)
- Oral > Solid > tablet: 150 mg (base)

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

- Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)

Indications

[Rheumatoid arthritis](#)

Section

Antimalarial medicines > Medicines for chemoprophylaxis in travellers

- Oral > Liquid: 50 mg per 5 mL (base)
- Oral > Solid > tablet: 150 mg (base)

Indications

[Malaria due to Plasmodium vivax](#)

Chlorothiazide [General information](#)

Section

Antihypertensive medicines

Indications

Therapeutic equivalent to [hydrochlorothiazide](#) for [Essential hypertension](#)

Section

Medicines used in heart failure

Indications

Therapeutic equivalent to [hydrochlorothiazide](#) for [Heart failure](#)

Chloroxylonol [General information](#)

Section

Disinfectants

- Local > Topical > Solution: 4.8%

Indications

[Phenol disinfectant, not elsewhere classified](#)

Chlorpromazine [General information](#)

Section

Medicines for psychotic disorders

- Oral > Liquid: 25 mg per 5 mL (hydrochloride)
- Oral > Solid: 100 mg (hydrochloride)
- Oral > Solid: 100 mg (hydrochloride); 10 mg (hydrochloride); 25 mg (hydrochloride); 50 mg (hydrochloride)
- Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (hydrochloride)

Indications

Therapeutic equivalent to [haloperidol](#) for [Schizophrenia or other primary psychotic disorders](#) [Schizophrenia or other primary psychotic disorders](#)

Chlortalidone [General information](#)

Section

Antihypertensive medicines

Indications

Therapeutic equivalent to [hydrochlorothiazide](#) for [Essential hypertension](#)

Section

Medicines used in heart failure

Indications

Therapeutic equivalent to [hydrochlorothiazide](#) for [Heart failure](#)

Chlortetracycline [General information](#)

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to [tetracycline](#) for [Other specified conjunctivitis](#) Therapeutic equivalent to [tetracycline](#) for [Infectious keratitis](#) Therapeutic equivalent to [tetracycline](#) for [Trachoma](#) Therapeutic equivalent to [tetracycline](#) for [Infectious blepharitis](#)

Cholera vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against cholera alone](#)

Ciclesonide [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [budesonide](#) for [Asthma](#)

Ciclopirox [General information](#)

Section

Dermatological medicines > Antifungal medicines

- Local > Topical > Solution: 80 mg per g (as hydroxypropyl chitosan)

Indications

[Onychomycosis](#)

Ciclosporin [General information](#)

Section

Immunomodulators for non-malignant disease

- Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
- Oral > Liquid: 100 mg per mL
- Oral > Solid > capsule: 25 mg

Indications

[Failure or rejection of transplanted organs or tissues](#)

Cimetidine [General information](#)

Section

Antiulcer medicines

- Oral > Solid: 200 mg
- Parenteral > General injections > unspecified: 200 mg in 2 mL ampoule

Indications

[Peptic ulcer, site unspecified](#) [Gastro-oesophageal reflux disease](#)

Ciprofloxacin [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 2 mg per mL (as hyclate)
- Oral > Liquid: 250 mg per 5 mL (anhydrous)
- Oral > Solid: 250 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

Indications

First choice

[Acute pyelonephritis \(mild to moderate\)](#) [Infectious gastroenteritis or colitis without specification of infectious agent](#) [Paratyphoid fever](#) [Typhoid fever](#) [Neutropenia \(low-risk\)](#) [Inflammatory and other diseases of prostate \(mild to moderate\)](#)

Second choice

[Cholera](#) [Cholera \[children\]](#) [Peritonitis \(mild-moderate\)](#) [Peritoneal abscess \(mild-moderate\)](#)

Other indications

[Bacterial infection of unspecified site](#)

Cisplatin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
- Parenteral > General injections > IV: 10 mg per 10 mL; 20 mg per 20 mL; 50 mg per 50 mL; 100 mg per 100 mL

- Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Other specified gliomas of brain](#) [Other specified malignant neoplasms of the ovary](#) [Other specified malignant neoplasms of bronchus or lung](#) [Malignant neoplasms of nasopharynx](#) [Germ cell tumour of testis](#) [Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Malignant neoplasms of cervix uteri](#) [Malignant neoplasms of hypopharynx](#) [Malignant neoplasms of oropharynx](#) [Malignant neoplasms of nasopharynx](#)

Cladribine [General information](#)

Section

Medicines for multiple sclerosis

- Oral > Solid > tablet: 10 mg

Indications

[Multiple sclerosis](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial

Indications

[Langerhans cell histiocytosis](#)

Clarithromycin [General information](#)

Section

Watch group antibiotics

- Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial powder for injection
- Oral > Solid > dosage form: 500 mg; 250 mg
- Oral > Solid > dosage form: 500 mg

Indications

First choice

co-prescribed with [cefotaxime Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#) co-prescribed with [ceftriaxone Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

Second choice

[Acute pharyngitis](#) co-prescribed with [amoxicillin + clavulanic acid Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

Other indications

[Helicobacter pylori associated gastric ulcer](#)

Clindamycin [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride) capsule
- Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection
- Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
- Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride)

Indications

First choice

[Necrotising fasciitis](#)

Second choice

[Bacterial infection of joint Osteomyelitis or osteitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Clofazimine [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dosage form: 100 mg; 50 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Section

Antileprosy medicines

- Oral > Solid > dosage form: 100 mg; 50 mg

Indications

[Leprosy](#)



Clomifene [General information](#)

Section

Ovulation inducers

- Oral > Solid: 50 mg (citrate)

Indications

[Female infertility without specification whether primary or secondary](#)



Clomipramine [General information](#)

Section

Medicines for obsessive compulsive disorders

- Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)

Indications

[Obsessive-compulsive disorder](#)



Clonazepam [General information](#)

Section

Medicines for central nervous system disorders

- Oral > Solid: 500 µg

Indications

[Generalised myoclonic seizure](#)



Clopidogrel [General information](#)

Section

Anti-platelet medicines

- Oral > Solid: 75 mg; 300 mg

Indications

[Acute ischaemic heart disease Presence of coronary angioplasty implant or graft](#)



Clotrimazole [General information](#)

Section

Antifungal medicines

- Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet

Indications

[Vulvovaginal candidosis](#)



Cloxacillin [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
- Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection
- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
- Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)

Indications

First choice

[Osteomyelitis or osteitis](#) [Bacterial infection of joint](#) [Bacterial cellulitis, erysipelas or lymphangitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Clozapine [General information](#)

Section

Medicines for psychotic disorders

- Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg

Indications

[Schizophrenia or other primary psychotic disorders](#)

Coagulation factor IX complex [General information](#)

Section

Coagulation factors

Indications

Therapeutic equivalent to [coagulation factor IX, plasma-derived](#) for [Coagulation defects, purpura or other haemorrhagic or related conditions](#). Therapeutic equivalent to [coagulation factor IX, plasma-derived](#) for [Haemophilia B](#)

Coagulation factor IX, plasma-derived [General information](#)

Section

Coagulation factors

- Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection

Indications

[Coagulation defects, purpura or other haemorrhagic or related conditions](#) [Haemophilia B](#)

Coagulation factor IX, recombinant [General information](#)

Section

Coagulation factors

- Parenteral > General injections > IV: 250 IU per mL in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection

Indications

[Haemophilia B](#)

Coagulation factor VIII, plasma-derived [General information](#)

Section

Coagulation factors

- Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection

Indications

[Haemophilia A](#)

Coagulation factor VIII, recombinant [General information](#)

Section

Coagulation factors

- Parenteral > General injections > IV: 250 IU in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection

Indications

[Haemophilia A](#)

Coal tar [General information](#)

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Local > Topical > Solution: 5%

Indications

[Psoriasis of unspecified type](#)

Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Cobimetinib [General information](#)

Section

Targeted therapies

Indications

Therapeutic equivalent to [trametinib](#) for [Other specified melanoma of skin](#)

Codeine [General information](#)

Section

Opioid analgesics

- Oral > Solid: 30 mg tablet (codeine phosphate)

Indications

[Pain](#)

Section

Antitussives

- Oral > Solid: 10 mg tablet (codeine phosphate)

Indications

[Cough](#)

Section

Medicines for diarrhoea

- Oral > Solid: 30 mg tablet (codeine phosphate)

Indications

[Diarrhoea](#)

Colchicine [General information](#)

Section

Medicines used to treat gout

- Oral > Solid: 0.5 mg

Indications

[Gout](#)

Colecalciferol [General information](#)

Section

Vitamins and minerals

Indications

Therapeutic equivalent to [ergocalciferol](#) for [Calcium deficiency](#) Therapeutic equivalent to [ergocalciferol](#) for [Vitamin D deficiency](#)

Colistin (injection) [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > unspecified: 1 million IU in vial (as colisthemethate sodium)
- Parenteral > General injections > unspecified: 1 million IU in vial (as colisthemethate sodium) (equivalent to 34 mg colistin base activity)

Indications

[Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales](#)



Compound sodium lactate solution [General information](#)

Section

Solutions correcting water, electrolyte and acid-base disturbances > Parenteral

- Parenteral > General injections > IV: injectable solution

Indications

[Other specified disorders of fluid, electrolyte or acid-base balance Hypovolaemic shock](#)



Condoms [General information](#)

Section

Barrier methods

- -

Indications

[Contact with health services for contraceptive management](#)



Copper-containing intrauterine device [General information](#)

Section

Intrauterine devices

- -

Indications

[Contact with health services for insertion of contraceptive device](#)



Crizotinib [General information](#)

Section

Targeted therapies

- Oral > Solid: 200 mg; 250 mg
- Oral > Solid > capsule: 200 mg; 250 mg

Indications

[Other specified malignant neoplasms of bronchus or lung Anaplastic large cell lymphoma, ALK-positive](#)



Cryoprecipitate (native) [General information](#)

Section

Blood and blood components

Indications

Therapeutic equivalent to [cryoprecipitate \(pathogen-reduced\)](#) for [Coagulation defects, purpura or other haemorrhagic or related conditions](#) Therapeutic equivalent to [cryoprecipitate \(pathogen-reduced\)](#) for [Obstetric haemorrhage](#) Therapeutic equivalent to [cryoprecipitate \(pathogen-reduced\)](#) for [Haemophilia A](#) Therapeutic equivalent to [cryoprecipitate \(pathogen-reduced\)](#) for [Von Willebrand disease](#)



Cryoprecipitate (pathogen-reduced) [General information](#)

Section

Blood and blood components

- Injection: frozen liquid in bag or lyophilized powder in vial containing:
 - > 50 IU Factor VIII
 - > 100 IU vWF
 - > 140 mg clottable fibrinogen per unit

Indications

[Coagulation defects, purpura or other haemorrhagic or related conditions Obstetric haemorrhage Haemophilia A Von Willebrand disease](#)



Cyanocobalamin [General information](#)

Section
Antianaemia medicines

Indications

[Anaemias or other erythrocyte disorders](#)



Cyclopentolate [General information](#)

Section

Diagnostic agents > Ophthalmic medicines

Indications

Therapeutic equivalent to [tropicamide](#) for [Cycloplegic drug](#)

Section

Ophthalmological preparations > Mydriatics

Indications

Therapeutic equivalent to [atropine](#) for [Anterior uveitis](#)



Cyclophosphamide [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 25 mg tablet
- Parenteral > General injections > unspecified: 500 mg in vial powder for injection
- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Oral > Solid > dosage form: 25 mg; 50 mg

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Malignant neoplasms of breast](#) [Diffuse large B-cell lymphoma, not otherwise specified](#) [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#) [Plasma cell myeloma](#) [Other specified malignant neoplasms of breast](#) [Follicular lymphoma](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Malignant trophoblastic neoplasms of placenta](#) [Lymphoid leukaemia, not elsewhere classified](#) [Rhabdomyosarcoma primary site](#) [Hodgkin lymphoma](#) [Other specified gliomas of brain](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#)



Cycloserine [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dosage form: 250 mg; 125 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Cytarabine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Acute myeloid leukaemia with recurrent genetic abnormalities](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Lymphoid leukaemia, not elsewhere classified](#) [Myeloid leukaemia](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#) [Langerhans cell histiocytosis](#)



Cytisine (cytisinicline) [General information](#)

Section

Medicines for nicotine use disorders

- Oral > Solid > tablet: 1.5 mg

Indications

[Nicotine dependence](#)



Dabigatran [General information](#)

Section

Medicines affecting coagulation

- Oral > Solid: 110 mg; 150 mg

Indications

[Other specified atrial fibrillation Venous thromboembolism](#)

Dabrafenib [General information](#)

Section

Targeted therapies

- Oral > Solid: 50 mg; 75 mg

Indications

[Other specified melanoma of skin](#)

Dacarbazine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection

Indications

[Hodgkin lymphoma](#)

Daclatasvir [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 30 mg (as dihydrochloride); 60 mg (as dihydrochloride)

Indications

[Chronic hepatitis C](#)

Daclatasvir + sofosbuvir [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 60 mg (as dihydrochloride) + 400 mg

Indications

[Chronic hepatitis C](#)

Dactinomycin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 500 µg in vial powder for injection

Indications

[Malignant trophoblastic neoplasms of placenta Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site Ewing sarcoma of bone and articular cartilage of unspecified sites](#)

Dalteparin [General information](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [enoxaparin](#) for [Acute ischaemic heart disease](#) Therapeutic equivalent to [enoxaparin](#) for [Venous thromboembolism](#)

Dapagliflozin [General information](#)

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [empagliflozin](#) for [Type 2 diabetes mellitus](#)

Dapsone [General information](#)

Section

Antileprosy medicines

- Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet

Indications

[Leprosy](#)

Daptomycin [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection

Indications

[Other specified bacterial diseases](#)

Daratumumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL

Indications

[Plasma cell myeloma](#)

Darbepoetin alfa [General information](#)

Section

Antianaemia medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Anaemia due to chronic disease](#)

Section

Supportive medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Drug-induced aplastic anaemia](#)

Darunavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Dasabuvir [General information](#)

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 250 mg tablet

Indications

[Chronic hepatitis C](#)

Dasatinib [General information](#)

Section

Targeted therapies

- Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet

Indications

[Chronic myeloid leukaemia, not elsewhere classified](#)

Daunorubicin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

Indications

[Acute myeloid leukaemia with recurrent genetic abnormalities](#) [Lymphoid leukaemia, not elsewhere classified](#)

[Myeloid leukaemia](#)

Deferasirox [General information](#)

Section

Medicines for haemoglobinopathies

- Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg
- Oral > Solid > tablet: 90 mg; 180 mg; 360 mg

Indications

[Other specified sickle cell disorders or other haemoglobinopathies Thalassaemias](#)

Deferiprone [General information](#)

Section

Medicines for haemoglobinopathies

Indications

Therapeutic equivalent to [deferasirox](#) for [Other specified sickle cell disorders or other haemoglobinopathies](#)

Therapeutic equivalent to [deferasirox](#) for [Thalassaemias](#)

Deferoxamine [General information](#)

Section

Antidotes and other substances used in poisonings > Specific

- Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

Indications

[Harmful effects of drugs, medicaments or biological substances, not elsewhere classified](#)

Section

Medicines for haemoglobinopathies

- Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

Indications

[Other specified sickle cell disorders or other haemoglobinopathies Thalassaemias](#)

Delaflaxacin [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 300 mg lyophilized powder for injection
- Oral > Solid: 450 mg

Indications

[Methicillin resistant Staphylococcus aureus](#)

Delamanid [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 25 mg
- Oral > Solid > tablet: 50 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Dengue vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against certain single viral diseases](#)

Desmopressin [General information](#)

Section

Medicines affecting coagulation

- Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)
- Local > Nasal > Spray: 150 µg per actuation (acetate)

Indications

[Haemophilia A Von Willebrand disease](#)

Dexamethasone [General information](#)

Section

Other medicines administered to the mother

- Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))

Indications

[Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy](#)

Section

Hormones and antihormones

- Oral > Liquid: 2 mg per 5 mL
- Oral > Solid: 2 mg; 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
- Oral > Liquid: 2 mg per 5 mL (as sodium phosphate)
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
- Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
- Oral > Solid > tablet: 4 mg (as dexamethasone base)

Indications

[Anaplastic large cell lymphoma, ALK-negative Lymphoid leukaemia, not elsewhere classified Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-positive](#)

Section

Antiallergics and medicines used in anaphylaxis

- Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate); 2 mg per 5 mL (as sodium phosphate)
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
- Oral > Solid > tablet: 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base); 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)

Indications

[Allergic or hypersensitivity conditions of unspecified type](#)

Section

Medicines for other common symptoms in palliative care

- Oral > Liquid: 2 mg per 5 mL (as sodium phosphate); 0.5 mg per 5 mL (as sodium phosphate)
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (dexamethasone phosphate (as sodium phosphate) equivalent to 3.3 mg dexamethasone base)
- Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base); 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base)

Indications

[Palliative care](#)

Section

Antiemetic medicines

- Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate); 2 mg per 5 mL (as sodium phosphate)
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
- Oral > Solid > tablet: 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base); 4 mg (as dexamethasone base); 2 mg (as dexamethasone base)

Indications

[Nausea or vomiting](#)

Dextran 40 [General information](#)

Section

Plasma substitutes

- .

Indications

[Hypovolaemia](#)

Dextran 70 [General information](#)

Section

Plasma substitutes

- Parenteral > General injections > IV: 6% injectable solution

Indications

[Hypovolaemia](#)

Diaphragms [General information](#)

Section
Barrier methods

◦ -

Indications

[Contact with health services for contraceptive management](#)

Diazepam [General information](#)

Section

Antiseizure medicines

- Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
- Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube

Indications

Therapeutic equivalent to [lorazepam](#) for [Status epilepticus Status epilepticus](#)

Section

Medicines for anxiety disorders

- Oral > Solid: 5 mg (scored); 2 mg (scored)

Indications

[Anxiety](#)

Section

Medicines for other common symptoms in palliative care

- Oral > Liquid: 2 mg per 5 mL
- Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
- Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube
- Parenteral > General injections > unspecified: 5 mg per mL
- Oral > Solid > tablet: 5 mg (scored); 10 mg (scored); 2 mg (scored)

Indications

[Palliative care](#)

Dicloxacillin [General information](#)

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

Didanosine [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution
- Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Diethylcarbamazine [General information](#)

Section

Antifilarials

- Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)

Indications

[Lymphatic filariasis](#)

Digitoxin [General information](#)

Section

Medicines used in heart failure

- Parenteral > General injections > IV: 0.2 mg in 1 mL ampoule
- Oral > Solid: 50 µg; 100 µg

Indications

[Heart failure](#)



Digoxin [General information](#)

Section

Antiarrhythmic medicines

- Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
- Oral > Liquid: 50 µg per mL
- Oral > Solid: 62.5 µg; 250 µg

Indications

[Cardiac arrhythmia](#)

Section

Medicines used in heart failure

- Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule; 100 µg per mL in 1 mL ampoule
- Oral > Liquid: 50 µg per mL
- Oral > Solid > tablet: 62.5 µg; 250 µg; 125 µg

Indications

[Heart failure](#)



Dihydroartemisinin + piperaquine [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > dispersible tablet: 20 mg + 160 mg (phosphate); 40 mg + 320 mg (phosphate)
- Oral > Solid > tablet: 40 mg + 320 mg (phosphate); 20 mg + 160 mg (phosphate); 60 mg + 480 (phosphate); 80 mg + 640 mg (phosphate)

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)



Dihydroergocryptine mesylate [General information](#)

Section

Medicines for central nervous system disorders

- Oral > Solid:

Indications

[Parkinson disease](#)



Diloxanide [General information](#)

Section

Antiamoebic and anti giardiasis medicines

- Oral > Solid: 500 mg (furoate)

Indications

[Amoebiasis](#)



Dimercaprol [General information](#)

Section

Antidotes and other substances used in poisonings > Specific

- Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule; 100 mg per mL in 3 mL ampoule

Indications

[Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified](#)



Diphtheria antitoxin [General information](#)

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

- Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial

Indications

[Need for immunization against diphtheria alone](#)



Diphtheria vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against diphtheria alone](#)

Diphtheria-pertussis-tetanus vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against diphtheria-tetanus-pertussis, combined](#)

Diphtheria-tetanus vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against combinations of infectious diseases](#)

Docetaxel [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL

Indications

[Other specified malignant neoplasms of breast](#) [Malignant neoplasms of breast](#) [Malignant neoplasms of prostate](#)
[Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Docusate sodium [General information](#)

Section

Medicines for other common symptoms in palliative care

- Oral > Liquid: 50 mg per 5 mL; 12.5 mg per 5 mL
- Oral > Solid > capsule: 100 mg

Indications

[Palliative care](#)

Dolasetron [General information](#)

Section

Medicines for other common symptoms in palliative care

Indications

Therapeutic equivalent to [ondansetron](#) for [Palliative care](#)

Section

Antiemetic medicines

Indications

Therapeutic equivalent to [ondansetron](#) for [Nausea or vomiting](#)

Dolutegravir [General information](#)

Section

Antiretrovirals > Integrase inhibitors

- Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Dolutegravir + lamivudine + tenofovir [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Donepezil [General information](#)

Section

Medicines for neurological disorders

- Oral > Liquid: 1 mg per mL (hydrochloride)
- Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 5 mg (hydrochloride) (orodispersible); 10 mg (hydrochloride) (orodispersible)

Indications

[Dementia due to Alzheimer disease](#)

Dopamine [General information](#)

Section

Medicines used in heart failure

- Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride)

Indications

[Cardiogenic shock Heart failure](#)

Dostarlimab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion

Indications

[Other specified malignant neoplasms of corpus uteri](#)

Doxorubicin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
- Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites Rhabdomyosarcoma primary site Follicular lymphoma Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Diffuse large B-cell lymphoma, not otherwise specified Hodgkin lymphoma Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis Lymphoid leukaemia, not elsewhere classified Other specified malignant neoplasms of breast Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Kaposi sarcoma of unspecified primary site](#)

Doxorubicin (as pegylated liposomal) [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

[Kaposi sarcoma of unspecified primary site](#)

Doxycycline [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
- Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
- Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
- Oral > Solid > dispersible tablet: 100 mg (as monohydrate)

- Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
- Oral > Solid > dosage form: 100 mg (as hyclate)

Indications

First choice

[Cholera](#) [Chlamydia trachomatis](#)

Second choice

[Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\)](#) [Cholera \[children\]](#) [Chronic obstructive pulmonary disease with acute exacerbation](#)

Other indications

[Bacterial infection of unspecified site](#)

Section

Antimalarial medicines > Medicines for chemoprophylaxis in travellers

- Oral > Liquid: 50 mg per 5 mL (calcium); 25 mg per 5 mL (monohydrate) powder for oral liquid
- Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
- Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)

Indications

[Malaria due to Plasmodium falciparum](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)

Indications

[Malaria due to Plasmodium falciparum](#)

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Solid: 100 mg (hydrochloride or hyclate)

Indications

[Malaria due to Plasmodium falciparum](#)

Dulaglutide [General information](#)

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for [Obesity](#) Therapeutic equivalent to [semaglutide](#) for [Type 2 diabetes mellitus](#)

Durvalumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 2.4 mL vial concentrate solution for infusion; 50 mg per mL in 10 mL vial concentrate solution for infusion

Indications

[Hepatocellular carcinoma of liver](#) [Malignant neoplasms of biliary tract, distal bile duct](#) [Malignant neoplasm of intrahepatic bile ducts](#) [Malignant neoplasms of gallbladder](#) [Other specified malignant neoplasms of bronchus or lung](#) [Malignant neoplasms of proximal biliary tract, cystic duct](#)

Edoxaban [General information](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) for [Other specified atrial fibrillation](#) Therapeutic equivalent to [dabigatran](#) for [Venous thromboembolism](#)

Efavirenz [General information](#)

Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

- Oral > Solid: 600 mg tablet

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Efavirenz + emtricitabine + tenofovir [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Efavirenz + lamivudine + tenofovir [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#) Therapeutic equivalent to [efavirenz + emtricitabine + tenofovir](#) for [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Eflornithine [General information](#)

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

- Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)

Indications

[Gambiense trypanosomiasis](#)

Elbasvir + grazoprevir [General information](#)

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 50 mg + 100 mg

Indications

[Chronic hepatitis C](#)

Eletriptan [General information](#)

Section

Medicines for acute migraine attacks

- Oral > Solid > tablet: 40 mg

Indications

Therapeutic equivalent to [sumatriptan](#) for [Migraine](#)

Elexacaftor + tezacaftor + ivacaftor [General information](#)

Section

Medicines for cystic fibrosis

- Oral > Solid > tablet: 50 mg + 25 mg + 37.5 mg; 100 mg + 50 mg + 75 mg
- Oral > Solid > granules: 80 mg + 40 mg + 60 mg in sachet; 100 mg + 50 mg + 75 mg in sachet

Indications

[Cystic fibrosis](#)

Emicizumab [General information](#)

Section

Medicines affecting coagulation

- Parenteral > General injections > SC: 12 mg per 0.4 mL in vial; 30 mg per mL in mL vial; 60 mg per 0.4 mL in vial; 105 mg per 0.7 mL in vial; 150 mg per mL in vial; 300 mg per 2 mL in vial

Indications

[Haemophilia A](#)

Empagliflozin [General information](#)

Section

Hypoglycaemic agents

- Oral > Solid: 10 mg; 25 mg

Indications

[Type 2 diabetes mellitus](#)



Emtricitabine [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 10 mg per mL
- Oral > Solid: 200 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Emtricitabine + rilpivirine + tenofovir alafenamide [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 25 mg + 25 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Emtricitabine + rilpivirine + tenofovir disoproxil fumarate [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Emtricitabine + tenofovir [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#) [Contact with or exposure to human immunodeficiency virus](#)



Emtricitabine + tenofovir alafenamide [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Enalapril [General information](#)

Section

Antihypertensive medicines

- Oral > Liquid: 1 mg per mL (as hydrogen maleate)
- Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)

Indications

[Essential hypertension](#)

Section

Medicines used in heart failure

- Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)

Indications

[Heart failure](#)

Encorafenib [General information](#)

Section

Targeted therapies

Indications

Therapeutic equivalent to [dabrafenib](#) for [Other specified melanoma of skin](#)

Enoxaparin [General information](#)

Section

Medicines affecting coagulation

- Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule

Indications

[Acute ischaemic heart disease Venous thromboembolism](#)

Entecavir [General information](#)

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 0.05 mg per mL
- Oral > Solid: 0.5 mg; 1 mg

Indications

[Chronic hepatitis B](#)

Enzalutamide [General information](#)

Section

Hormones and antihormones

- Oral > Solid: 40 mg

Indications

Therapeutic equivalent to [abiraterone](#) for [Malignant neoplasms of prostate Malignant neoplasms of prostate](#)

Ephedrine [General information](#)

Section

Local anaesthetics

- Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)

Indications

[Cardiac complications of anaesthesia during labour or delivery](#)

Epinephrine [General information](#)

Section

Antiarrhythmic medicines

- Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)

Indications

[Cardiac arrest](#)

Section

Ophthalmological preparations > Mydriatics

- Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)

Indications

[Primary open-angle glaucoma](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

- Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)

Indications

[Chronic obstructive pulmonary disease Asthma](#)

Section

Antiallergics and medicines used in anaphylaxis

- Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)

Indications

[Anaphylaxis](#)

Epoetin alfa [General information](#)

Section

Antianaemia medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Anaemia due to chronic disease](#)

Section

Supportive medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Drug-induced aplastic anaemia](#)

Epoetin beta [General information](#)

Section

Antianaemia medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Anaemia due to chronic disease](#)

Section

Supportive medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Drug-induced aplastic anaemia](#)

Epoetin theta [General information](#)

Section

Antianaemia medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Anaemia due to chronic disease](#)

Eptinezumab [General information](#)

Section

Medicines for migraine prophylaxis

Indications

Therapeutic equivalent to [fremanezumab](#) for [Chronic migraine](#)

Equine rabies immunoglobulin [General information](#)

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

- Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial

Indications

[Rabies](#)

Eravacycline [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 50 mg lyophilized powder for injection

Indications

[Carbapenem resistant Enterobacterales](#)

Erenumab [General information](#)

Section

Medicines for migraine prophylaxis

Indications

Therapeutic equivalent to [fremanezumab](#) for [Chronic migraine](#)

Ergocalciferol [General information](#)

Section

Vitamins and minerals

- Oral > Liquid: 250 µg per mL (10 000 IU per mL)
- Oral > Solid: 1.25 mg (50 000 IU)

Indications

[Calcium deficiency Vitamin D deficiency](#)



Ergometrine [General information](#)

Section

Uterotonics

- Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)

Indications

[Postpartum haemorrhage](#)



Erlotinib [General information](#)

Section

Targeted therapies

- Oral > Solid: 100 mg; 150 mg

Indications

[Other specified malignant neoplasms of bronchus or lung](#)



Erythromycin [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)
- Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)
- Oral > Solid: 250 mg (as stearate or ethylsuccinate)

Indications

Second choice

Therapeutic equivalent to [clarithromycin](#) for [Acute pharyngitis](#)

Other indications

[Bacterial infection of unspecified site](#)



Erythropoiesis-stimulating agents [General information](#)

Section

Antianaemia medicines

- Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe

Indications

[Anaemia due to chronic disease](#)

Section

Supportive medicines

- Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial (single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose)

Indications

[Drug-induced aplastic anaemia](#)



Estradiol [General information](#)

Section

Estrogens

- Oral > Solid > tablet: 0.5 mg; 1 mg; 2 mg

Indications

[Hypopituitarism Gonadotropin deficiency Turner syndrome](#)



Estradiol cypionate + medroxyprogesterone acetate [General information](#)

Section

Injectable hormonal contraceptives

- Parenteral > General injections > IM: 5 mg + 25 mg

Indications

[Contact with health services for reasons associated with reproduction](#)



Etanercept [General information](#)

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for [Axial spondyloarthritis](#) Therapeutic equivalent to [adalimumab](#) for [Crohn disease site](#) Therapeutic equivalent to [adalimumab](#) for [Rheumatoid arthritis](#)

Section

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab](#) for [Juvenile idiopathic arthritis](#)

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to [adalimumab](#) for [Psoriasis of unspecified type](#)



Ethambutol [General information](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL
- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)

Indications

[Other specified tuberculosis Tuberculosis](#)



Ethambutol + isoniazid [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 400 mg + 150 mg tablet

Indications

[Tuberculosis](#)



Ethambutol + isoniazid + pyrazinamide + rifampicin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet

Indications

[Tuberculosis](#)



Ethambutol + isoniazid + rifampicin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 275 mg + 75 mg + 150 mg tablet

Indications

[Tuberculosis](#)



Ethanol [General information](#)

Section

Antiseptics

- Local > Topical > Solution: 70% (denatured)

Indications

[Denatured alcohol](#)



Ether [General information](#)

Section

General anaesthetics and oxygen > Inhalational medicines

- Respiratory > Inhalation > solution:

Indications

[Anaesthetics and therapeutic gases](#)



Ethinylestradiol + etonogestrel [General information](#)

Section

Intravaginal contraceptives

- Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg

Indications

[Contact with health services for contraceptive management](#)



Ethinylestradiol + levonorgestrel [General information](#)

Section

Oral hormonal contraceptives

- Oral > Solid: 50 µg + 250 µg [4]
- Oral > Solid: 30 µg + 150 µg

Indications

[Contact with health services for postcoital contraception](#) [Contact with health services for contraceptive management](#)



Ethinylestradiol + norethisterone [General information](#)

Section

Oral hormonal contraceptives

- Oral > Solid: 35 µg + 1 mg

Indications

[Contact with health services for contraceptive management](#)



Ethionamide [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 125 mg
- Oral > Solid > tablet: 250 mg

Indications

[Tuberculous meningitis](#) [Multi-drug resistant Mycobacterium tuberculosis](#)



Ethosuximide [General information](#)

Section

Antiseizure medicines

- Oral > Liquid: 250 mg per 5 mL
- Oral > Solid: 250 mg

Indications

[Absence seizures, typical](#)



Etonogestrel-releasing implant [General information](#)

Section

Implantable contraceptives

- Implant > Subdermal: 68 mg single rod

Indications

[Contact with health services for insertion of contraceptive device](#)



Etoposide [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule
- Oral > Solid: 100 mg capsule
- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
- Oral > Solid: 100 mg capsule; 50 mg capsule

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Lymphoid leukaemia, not elsewhere classified](#) [Myeloid leukaemia](#) [Other specified malignant neoplasms of the ovary](#) [Other specified malignant neoplasms of bronchus or lung](#) [Germ cell tumour of testis](#) [Malignant trophoblastic neoplasms of placenta](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Hodgkin lymphoma](#) [Retinoblastoma](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#)



Everolimus [General information](#)

Section

Targeted therapies

- Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg
- Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg

Indications

[Other specified gliomas of brain](#)



Exenatide [General information](#)

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for [Obesity](#)



Fentanyl [General information](#)

Section

Opioid analgesics

- Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour
- Oral > Solid: 100 to 800 µg sub-lingual tablet (as citrate); 200 to 1600 µg lozenge (as citrate)
- Oral > Other: 200 to 1200 µg buccal film (as citrate)

Indications

[Chronic cancer pain](#) [Other specified chronic cancer related pain](#)



Ferrous salt [General information](#)

Section

Antianaemia medicines

- Oral > Liquid: 25 mg per mL elemental iron; 9 mg per mL elemental iron
- Oral > Solid > tablet: 60 to 65 mg elemental iron

Indications

[Iron deficiency anaemia](#)



Ferrous salt + folic acid [General information](#)

Section

Antianaemia medicines

- Oral > Solid: 60 mg iron + 2.8 mg
- Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg

Indications

[Iron deficiency anaemia](#) [Iron deficiency anaemia](#) [Spina bifida](#) [Clefts of lip, alveolus or palate](#) [Anencephaly or similar anomalies](#)



Fexinidazole [General information](#)

Section

Medicines for the treatment of 1st stage African trypanosomiasis

- Oral > Solid > tablet: 600 mg
- Oral > Solid: 600 mg

Indications

[Rhodesiense trypanosomiasis](#) [Gambiense trypanosomiasis](#)

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

- Oral > Solid > tablet: 600 mg
- Oral > Solid: 600 mg

Indications

[Rhodesiense trypanosomiasis](#) [Gambiense trypanosomiasis](#)

Fexofenadine [General information](#)

Section

Antiallergics and medicines used in anaphylaxis

Indications

Therapeutic equivalent to [loratadine](#) for [Allergic or hypersensitivity conditions of unspecified type](#)

Fifth generation cephalosporins [General information](#)

Section

Reserve group antibiotics

◦ .

Indications

[Other specified bacterial diseases](#)

Filgrastim [General information](#)

Section

Immunomodulators

- Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial

Indications

[Acquired neutropaenia](#)

Fingolimod [General information](#)

Section

Immunomodulators for non-malignant disease

- Oral > Solid: 0.25 mg; 0.5 mg

Indications

[Relapsing-remitting multiple sclerosis](#)

Flomoxef [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection

Indications

[Other specified other antibiotic resistant Enterobacterales](#)

Flucloxacillin [General information](#)

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

Fluconazole [General information](#)

Section

Antifungal medicines

- Parenteral > General injections > IV: 2 mg per mL in vial
- Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid
- Oral > Solid > capsule: 50 mg

Indications

[Cryptococcosis](#) [Candidosis](#)

Flucytosine [General information](#)

Section

Antifungal medicines

- Parenteral > General injections > IV: 2.5 g per 250 mL infusion
- Oral > Solid: 250 mg capsule

Indications

[Cryptococcosis](#)



Fludarabine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
- Oral > Solid: 10 mg tablet (fludarabine phosphate)

Indications

[Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#)



Fludrocortisone [General information](#)

Section

Adrenal hormones and synthetic substitutes

- Oral > Liquid: 100 µg per mL
- Oral > Solid > tablet: 100 µg (acetate)

Indications

[Adrenocortical insufficiency](#)



Fluorescein [General information](#)

Section

Diagnostic agents > Ophthalmic medicines

- Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)

Indications

[Fluorescein](#)



Fluoride [General information](#)

Section

Dental medicines and preparations

- Local > Dental > Gel: 2500 to 12500 ppm fluoride (any type)
- Local > Dental > Toothpaste, cream or gel: 1000 to 1500 ppm fluoride (any type)
- Local > Dental > Mouthrinse: 230 to 900 ppm fluoride (any type)
- Local > Dental > Varnish: 22500 ppm fluoride (any type)

Indications

[Dental caries](#)



Fluorouracil [General information](#)

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Local > Topical > Ointment: 5%

Indications

[Plantar warts](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule
- Parenteral > General injections > IV: 50 mg per mL in vial

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Malignant neoplasms of nasopharynx](#) [Malignant neoplasm metastasis in large intestine](#) [Malignant neoplasms of breast](#) [Malignant neoplasms of rectum](#) [Malignant neoplasms of colon](#)



Fluoxetine [General information](#)

Section

Medicines for depressive disorders

- Oral > Solid: 20 mg (as hydrochloride)

Indications

[Depressive disorders](#)

Section

Medicines for anxiety disorders

- Oral > Solid: 20 mg (as hydrochloride)

Indications

[Generalised anxiety disorder](#) [Panic disorder](#) [Social anxiety disorder](#)

Section

Medicines for other common symptoms in palliative care

- Oral > Solid: 20 mg (as hydrochloride)

Indications

[Palliative care](#)

Section

Medicines for obsessive compulsive disorders

- Oral > Solid: 20 mg (as hydrochloride)

Indications

[Obsessive-compulsive disorder](#)



Fluphenazine [General information](#)

Section

Medicines for psychotic disorders

- Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate)

Indications

[Schizophrenia or other primary psychotic disorders](#)



Flutamide [General information](#)

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [bicalutamide](#) for [Malignant neoplasms of prostate](#)



Fluticasone [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [budesonide](#) for [Asthma](#)



Fluticasone + formoterol [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [budesonide + formoterol](#) for [Asthma](#)



Fluticasone furoate + vilanterol [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [budesonide + formoterol](#) for [Asthma](#)



Fluvastatin [General information](#)

Section

Lipid-lowering agents

Indications

Therapeutic equivalent to [simvastatin](#) for [Mixed hyperlipidaemia](#) Therapeutic equivalent to [simvastatin](#) for [Coronary atherosclerosis](#)



Folic acid [General information](#)

Section

Antianaemia medicines

- Oral > Solid: 400 µg

- Oral > Liquid: 1 mg per mL
- Oral > Solid: 1 mg tablet; 5 mg tablet

Indications

[Cephalocele Anencephaly or similar anomalies Spina bifida Folate deficiency anaemia](#)

Fomepizole [General information](#)

Section

Antidotes and other substances used in poisonings > Specific

- Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule or vial (sulfate); 1 g per mL in 1.5 mL ampoule or vial (base)

Indications

[Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified](#)

Fosfomycin (injection) [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection

Indications

[Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales](#)

Fourth generation cephalosporins [General information](#)

Section

Watch group antibiotics

- .

Indications

[Other specified bacterial diseases](#)

Fremanezumab [General information](#)

Section

Medicines for migraine prophylaxis

- Parenteral > General injections > SC: 225 mg per 1.5 mL in pre-filled syringe

Indications

[Chronic migraine](#)

Fresh-frozen plasma [General information](#)

Section

Blood and blood components

- Parenteral > General injections > IV:

Indications

[Blood transfusion without reported diagnosis](#)

Fulvestrant [General information](#)

Section

Hormones and antihormones

- Parenteral > General injections > IV: 250 mg per 5 mL

Indications

[Malignant neoplasms of breast](#)

Furosemide [General information](#)

Section

Medicines used in heart failure

- Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
- Oral > Solid > tablet: 40 mg; 20 mg

Indications

[Heart failure](#)

Section

Diuretics

- Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
- Oral > Solid > tablet: 40 mg; 20 mg

Indications

[Anuria or oliguria Oedema](#)



Gabapentin [General information](#)

Section

Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)

- Oral > Solid: 100 mg; 200 mg; 300 mg; 400 mg; 600 mg; 800 mg

Indications

[Neuropathic pain](#)



Galcanezumab [General information](#)

Section

Medicines for migraine prophylaxis

Indications

Therapeutic equivalent to [fremanezumab](#) for [Chronic migraine](#)



Gallamine [General information](#)

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

- Parenteral > General injections > IV: 40 mg per mL in 2 mL ampoule (gallamine triethiodide)

Indications

[Muscle relaxants](#)



Gatifloxacin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 200 mg; 400 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Gefitinib [General information](#)

Section

Targeted therapies

Indications

Therapeutic equivalent to [erlotinib](#) for [Other specified malignant neoplasms of bronchus or lung](#)



Gemcitabine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection

Indications

[Other specified carcinomas of ovary](#) [Other specified malignant neoplasms of bronchus or lung](#)



Gentamicin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

Indications

First choice

co-prescribed with [amoxicillin Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) co-prescribed with [ampicillin Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-

prescribed with [ampicillin Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#) co-prescribed with [benzylpenicillin Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#) co-prescribed with [benzylpenicillin Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#)

Second choice

[Gonococcal infection Other specified prophylactic measures](#)

Other indications

[Bacterial infection of unspecified site](#)

Section

Ophthalmological preparations > Anti-infective agents

- Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)

Indications

[Other specified conjunctivitis Infectious blepharitis](#)

Glass ionomer cement [General information](#)

Section

Dental medicines and preparations

- Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid

Indications

[Dental caries](#)

Glatiramer acetate [General information](#)

Section

Medicines for multiple sclerosis

- Parenteral > General injections > SC: 20 mg per mL; 40 mg per mL
- Parenteral > General injections > SC: 20 mg per mL in pre-filled syringe; 40 mg per mL in pre-filled syringe

Indications

[Relapsing-remitting multiple sclerosis Multiple sclerosis](#)

Glecaprevir + pibrentasvir [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid: 50 mg + 20 mg granules
- Oral > Solid > tablet: 100 mg + 40 mg

Indications

[Chronic hepatitis C](#)

Glibenclamide [General information](#)

Section

Hypoglycaemic agents

- Oral > Solid: 5 mg; 2.5 mg

Indications

[Type 2 diabetes mellitus](#)

Gliclazide [General information](#)

Section

Hypoglycaemic agents

- Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release

Indications

[Type 2 diabetes mellitus](#)

Glucagon [General information](#)

Section

Medicines for hypoglycaemia

- Parenteral > General injections > unspecified: 1 mg per mL as powder and diluent

Indications

[Hypoglycaemia in the context of diabetes](#)

Glucose [General information](#)

Section

Solutions correcting water, electrolyte and acid-base disturbances > Parenteral

- Parenteral > General injections > IV: 5% isotonic; 10% hypertonic
- Parenteral > General injections > IV: 50% hypertonic

Indications

[Other specified disorders of fluid, electrolyte or acid-base balance](#) [Hypoglycaemia without associated diabetes](#)

Glucose + sodium chloride [General information](#)

Section

Solutions correcting water, electrolyte and acid-base disturbances > Parenteral

- Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na⁺ 30 mmol/L and Cl⁻ 30 mmol/L; 5% + 0.9% (equivalent to Na⁺ 150 mmol/L and Cl⁻ 150 mmol/L); 5% + 0.45% (equivalent to Na⁺ 75 mmol/L and Cl⁻ 75 mmol/L)

Indications

[Other specified disorders of fluid, electrolyte or acid-base balance](#)

Glutaral [General information](#)

Section

Disinfectants

- Local > Topical > Solution: 2%

Indications

[Glutaral nonmedicinal](#)

Glycerol [General information](#)

Section

Dermatological medicines > Moisturizers

- Local > Topical > Cream: 15 to 20%

Indications

[Atopic eczema](#)

Glyceryl trinitrate [General information](#)

Section

Antianginal medicines

- Oral > Solid: 500 µg sublingual tablet

Indications

[Angina pectoris](#)

Glycopyrronium [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [tiotropium bromide](#) for [Chronic obstructive pulmonary disease](#)

Golimumab [General information](#)

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for [Axial spondyloarthritis](#) Therapeutic equivalent to [adalimumab](#) for [Crohn disease site](#) Therapeutic equivalent to [adalimumab](#) for [Rheumatoid arthritis](#)

Section

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab](#) for [Juvenile idiopathic arthritis](#)

Goserelin [General information](#)

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [leuprorelin](#) for [Malignant neoplasms of breast](#) Therapeutic equivalent to [leuprorelin](#) for [Malignant neoplasms of prostate](#)

Granisetron [General information](#)

Section

Medicines for other common symptoms in palliative care

Indications

Therapeutic equivalent to [ondansetron](#) for [Palliative care](#)

Section

Antiemetic medicines

Indications

Therapeutic equivalent to [ondansetron](#) for [Nausea or vomiting](#)

Griseofulvin [General information](#)

Section

Antifungal medicines

- Oral > Liquid: 125 mg per 5 mL
- Oral > Solid: 125 mg; 250 mg

Indications

[Dermatophytosis](#)

Haemophilus influenzae type b vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against single bacterial diseases](#)

Haloperidol [General information](#)

Section

Medicines for other common symptoms in palliative care

- Oral > Liquid: 2 mg per mL
- Oral > Solid: 0.5 mg; 2 mg; 5 mg
- Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule

Indications

[Palliative care](#)

Section

Medicines for psychotic disorders

- Parenteral > General injections > IM: 5 mg per mL in ampoule
- Oral > Solid: 2 mg; 5 mg

Indications

[Schizophrenia or other primary psychotic disorders](#)

Haloperidol decanoate [General information](#)

Section

Medicines for psychotic disorders

Indications

Therapeutic equivalent to [fluphenazine](#) for [Schizophrenia or other primary psychotic disorders](#)

Halothane [General information](#)

Section

General anaesthetics and oxygen > Inhalational medicines

- Respiratory > Inhalation > liquid:

Indications

[Anaesthetics and therapeutic gases](#)

Heparin sodium [General information](#)

Section

Medicines affecting coagulation

- Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule or vial; 20000 IU per mL in 1 mL ampoule or vial; 5000 IU per mL in 1 mL ampoule or vial

Indications

[Acute ischaemic heart disease](#) [Unstable angina](#) [Venous thromboembolism](#)



Hepatitis A vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against viral hepatitis](#)



Hepatitis B vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against viral hepatitis](#)



Hepatitis E vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against viral hepatitis](#)



Homatropine [General information](#)

Section

Ophthalmological preparations > Mydriatics

- Local > Ophthalmological > Solution (eye drops): 2% (hydrobromide)

Indications

[Anterior uveitis](#) Therapeutic equivalent to [atropine](#) for [Anterior uveitis](#)



Human papilloma virus (HPV) vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against certain single viral diseases](#)



Hydralazine [General information](#)

Section

Antihypertensive medicines

- Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)
- Oral > Solid: 50 mg tablet; 25 mg tablet (hydrochloride)
- Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)

Indications

[Essential hypertension](#) [Gestational hypertension](#)



Hydrochlorothiazide [General information](#)

Section

Antihypertensive medicines

- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 25 mg; 12.5 mg

Indications

[Essential hypertension](#)

Section

Medicines used in heart failure

- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 25 mg

Indications

[Heart failure](#)

Section

Diuretics

- Oral > Solid > dosage form: 25 mg; 12.5 mg

Indications

[Oedema](#)

Hydrocortisone [General information](#)

Section

Hormones and antihormones

- Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)

Indications

[Lymphoid leukaemia, not elsewhere classified](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)
[Burkitt lymphoma including Burkitt leukaemia](#)

Section

Ophthalmological preparations > Anti-inflammatory agents

- Local > Ophthalmological > Ointment: 1% (acetate)

Indications

[Scleritis Anterior uveitis](#)

Section

Antiallergics and medicines used in anaphylaxis

- Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)

Indications

[Anaphylaxis](#)

Section

Anti-inflammatory medicines

- Local > Rectal > Suppository: 25 mg (acetate)
- Local > Rectal > Retention enema: 100 mg per 60 mL

Indications

[Crohn disease site Ulcerative colitis](#)

Section

Dermatological medicines > Anti-inflammatory and antipruritic medicines

- Local > Topical > Cream: 1% (acetate)
- Local > Topical > Ointment: 1% (acetate)

Indications

[Dermatitis or eczema Pruritus due to skin disorder Psoriasis of unspecified type Lichen planus](#)

Section

Adrenal hormones and synthetic substitutes

- Oral > Solid > tablet: 5 mg; 10 mg; 20 mg
- Oral > Solid > granules: 0.5 mg in capsule; 1 mg in capsule; 2 mg in capsule; 5 mg in capsule

Indications

[Adrenocortical insufficiency](#)

Hydromorphone [General information](#)

Section

Opioid analgesics

Indications

Therapeutic equivalent to [morphine](#) for [Pain](#)

Hydroxocobalamin [General information](#)

Section

Antianaemia medicines

- Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)

Indications

[Megaloblastic anaemia due to vitamin B12 deficiency](#)

Hydroxycarbamide (hydroxyurea) [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
- Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg

Indications

[Squamous cell carcinoma of oropharynx](#) [Chronic myeloid leukaemia, not elsewhere classified](#)

Section

Medicines for haemoglobinopathies

- Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg

Indications

[Other specified sickle cell disorders or other haemoglobinopathies](#)

Hydroxychloroquine [General information](#)

Section

Antimalarial medicines > Medicines for chemoprevention

Indications

Therapeutic equivalent to [chloroquine](#) for [Malaria due to Plasmodium falciparum](#)

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

- Oral > Solid: 200 mg (as sulfate)

Indications

[Systemic lupus erythematosus](#) [Cutaneous lupus erythematosus of unspecified type](#)

Hyoscine butylbromide [General information](#)

Section

Medicines for other common symptoms in palliative care

- Parenteral > General injections > unspecified: 20 mg per mL injection

Indications

[Palliative care](#)

Hypochlorous acid [General information](#)

Section

Disinfectants

- Solution (aqueous): containing hypochlorous acid \geq 150 parts per million

Indications

[Disinfectant, not elsewhere classified](#)

Section

Antiseptics

- Solution (aqueous): containing hypochlorous acid \geq 150 parts per million

Indications

[Hypochlorite](#)

Hypromellose [General information](#)

Section

Ophthalmological preparations

- Local > Ophthalmological > Solution (eye drops): 0.3%

Indications

[Keratoconjunctivitis sicca](#)

Ibrutinib [General information](#)

Section

Targeted therapies

- Oral > Solid: 140 mg

Indications

[Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#)

Ibuprofen [General information](#)

Section

Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)

- Oral > Liquid: 200 mg per 5 mL; 100 mg per 5 mL
- Oral > Solid > tablet: 200 mg; 400 mg; 600 mg

Indications

[Pain](#)

Section

Medicines for acute migraine attacks

- Oral > Liquid: 100 mg per 5 mL; 200 mg per 5 mL
- Oral > Solid > tablet: 200 mg; 400 mg

Indications

[Migraine](#)



Idoxuridine [General information](#)

Section

Ophthalmological preparations > Anti-infective agents

- Local > Ophthalmological > Solution (eye drops): 0.1%
- Local > Ophthalmological > Ointment: 0.2%

Indications

[Herpes simplex keratitis](#)



Ifosfamide [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

[Other specified malignant neoplasms of the ovary](#) [Germ cell tumour of testis](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Rhabdomyosarcoma primary site](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#)



Imatinib [General information](#)

Section

Targeted therapies

- Oral > Solid: 100 mg; 400 mg

Indications

[B lymphoblastic leukaemia or lymphoma with t\(9:22\) \(q34;q11.2\); BCR-ABL1](#) [Chronic myeloid leukaemia, not elsewhere classified](#) [Gastrointestinal stromal tumour of unspecified gastrointestinal sites](#)



Imipenem + cilastatin [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

Indications

Second choice

Therapeutic equivalent to [meropenem](#) for [Peritonitis \(severe\)](#) Therapeutic equivalent to [meropenem](#) for [Peritoneal abscess \(severe\)](#) Therapeutic equivalent to [meropenem](#) for [Neutropenia \(high-risk\)](#)

Other indications

[Pseudomonas aeruginosa resistant to other antibiotic](#) [Antibiotic resistant Acinetobacter baumannii](#)

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to [meropenem](#) for [Multi-drug resistant Mycobacterium tuberculosis](#)



Imipenem + cilastatin + relebactam [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection
- Parenteral > General injections > IV: 500 mg (as monohydrate) + 500 mg (as sodium) + 250 mg (as monohydrate) powder for injection

Indications

[Carbapenem resistant Enterobacterales](#) [Other specified other antibiotic resistant Enterobacterales](#) [Carbapenem-resistant Pseudomonas aeruginosa](#)



Indapamide [General information](#)

Section

Antihypertensive medicines

Indications

Therapeutic equivalent to [hydrochlorothiazide](#) for [Essential hypertension](#)

Section

Medicines used in heart failure

Indications

Therapeutic equivalent to [hydrochlorothiazide](#) for [Heart failure](#)

Indinavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 400 mg (as sulfate)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Infliximab [General information](#)

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for [Axial spondyloarthritis](#) Therapeutic equivalent to [adalimumab](#) for [Crohn disease site](#) Therapeutic equivalent to [adalimumab](#) for [Rheumatoid arthritis](#)

Section

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab](#) for [Juvenile idiopathic arthritis](#)

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to [adalimumab](#) for [Psoriasis of unspecified type](#)

Influenza vaccine (seasonal) [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against influenza](#)

Insulin (analogue, long-acting) [General information](#)

Section

Insulins

- Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution; 100 IU per mL in 10 mL vial solution

Indications

[Type 2 diabetes mellitus](#) [Type 1 diabetes mellitus](#)

Insulin (analogue, rapid-acting) [General information](#)

Section

Insulins

- Parenteral > General injections > SC: 100 IU per 1 mL in 10 mL vial; 100 IU per 1 mL in 3 mL cartridge; 100 IU per 1 mL in 3 mL pre-filled pen

Indications

[Type 1 diabetes mellitus](#) [Type 2 diabetes mellitus](#)

Insulin (human, intermediate-acting) [General information](#)

Section

Insulins

- Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or

isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin

Indications

[Type 2 diabetes mellitus](#) [Type 1 diabetes mellitus](#)



Insulin (human, short-acting) [General information](#)

Section

Insulins

- Parenteral > General injections > SC: 40 IU per mL in 10 mL vial solution; 100 IU per mL in 10 mL vial solution; 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution

Indications

[Type 2 diabetes mellitus](#) [Type 1 diabetes mellitus](#)



Insulin analogues [General information](#)

Section

Insulins

- Not specified

Indications

[Type 2 diabetes mellitus](#) [Type 1 diabetes mellitus](#)



Insulin aspart [General information](#)

Section

Insulins

- Parenteral > General injections > SC: 100 IU per mL in 110 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
- Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Indications

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for [Type 1 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for [Type 2 diabetes mellitus](#)



Insulin degludec [General information](#)

Section

Insulins

- Parenteral > General injections > SC: 100 units per mL

Indications

Therapeutic equivalent to [insulin glargine](#) for [Type 1 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for [Type 2 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for [Type 1 diabetes mellitus](#)



Insulin detemir [General information](#)

Section

Insulins

Indications

Therapeutic equivalent to [insulin glargine](#) for [Type 1 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for [Type 2 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for [Type 1 diabetes mellitus](#)



Insulin glargine [General information](#)

Section

Insulins

- Parenteral > General injections > SC: 100 units per mL

Indications

[Type 1 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for [Type 2 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for [Type 1 diabetes mellitus](#)



Insulin glulisine [General information](#)

Section

Insulins

- Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Indications

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for [Type 1 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for [Type 2 diabetes mellitus](#)

Insulin lispro [General information](#)

Section

Insulins

- Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Indications

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for [Type 1 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for [Type 2 diabetes mellitus](#)

Intraperitoneal dialysis solution [General information](#)

Section

Peritoneal dialysis solution

- Solution: of appropriate composition in accordance with local clinical guidelines.

Indications

[Care involving peritoneal dialysis](#)

Iodine [General information](#)

Section

Antiseptics

Indications

Therapeutic equivalent to [povidone iodine](#) for [Povidone iodine](#)

Section

Vitamins and minerals

- Parenteral > General injections > IM: 480 mg per mL in 10 mL ampoule or vial iodized oil (oral or injectable)

Indications

[Iodine deficiency](#)

Iohexol [General information](#)

Section

Diagnostic agents > Radiocontrast media

- Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule

Indications

[X-ray contrast media, iodinated](#)

Ipecacuanha [General information](#)

Section

Antidotes and other substances used in poisonings > Non-specific

- Oral > Liquid: 0.14% ipecacuanha alkaloids calculated as emetine

Indications

[Unspecified injury, poisoning or certain other consequences of external causes](#)

Ipilimumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion

Indications

[Renal cell carcinoma of kidney, except renal pelvis](#) [Squamous cell carcinoma of oesophagus](#) [Melanoma of skin](#) [Other specified malignant neoplasms of bronchus or lung](#)

Ipratropium bromide [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

- Respiratory > Inhalation > solution: 20 µg per actuation in pressurized metered dose inhaler

Indications

[Chronic obstructive pulmonary disease Asthma](#)



Irinotecan [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial

Indications

[Malignant neoplasm metastasis in large intestine Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site](#)



Isoflurane [General information](#)

Section

General anaesthetics and oxygen > Inhalational medicines

- Respiratory > Inhalation > liquid:

Indications

[Anaesthetics and therapeutic gases](#)



Isoniazid [General information](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 100 mg per mL
- Oral > Solid > dispersible tablet: 100 mg (scored)
- Oral > Solid > tablet: 100 mg; 300 mg

Indications

[Other specified tuberculosis Tuberculosis](#)



Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim [General information](#)

Section

Medicines for prevention of HIV-related opportunistic infections

- Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)

Indications

[Other specified prophylactic measures](#)



Isoniazid + rifampicin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 50 mg + 75 mg
- Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg

Indications

[Tuberculosis](#)



Isoniazid + rifapentine [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 300 mg + 300 mg tablet (scored)

Indications

[Latent tuberculosis](#)



Isoprenaline [General information](#)

Section

Antiarrhythmic medicines

- Parenteral > General injections > IV: 20 µg per mL in ampoule (hydrochloride)
- Oral > Solid: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)

Indications

[Bradycardia Cardiogenic shock](#)



Isosorbide dinitrate [General information](#)

Section

Antianginal medicines

- Oral > Solid: 5 mg sublingual tablet

Indications

[Angina pectoris](#)



Itraconazole [General information](#)

Section

Antifungal medicines

- Oral > Liquid: 10 mg per mL
- Oral > Solid: 100 mg

Indications

[Chronic pulmonary aspergillosis](#) [Chromoblastomycosis](#) [Histoplasmosis](#) [Talaromycosis](#) [Sporotrichosis](#)
[Paracoccidioidomycosis](#)



Ivacaftor [General information](#)

Section

Medicines for cystic fibrosis

- Oral > Solid > tablet: 75 mg; 150 mg
- Oral > Solid > granules: 59.5 mg; 75 mg

Indications

[Cystic fibrosis](#)



Ivermectin [General information](#)

Section

Intestinal anthelmintics

- Oral > Solid > tablet: 3 mg

Indications

[Strongyloidiasis](#) [Ascariasis](#) [Trichuriasis](#) [Ancylostomiasis](#) [Hookworm diseases](#)

Section

Medicines for ectoparasitic infections

- Oral > Solid > tablet: 3 mg

Indications

[Scabies](#)

Section

Antifilarials

- Oral > Solid > tablet: 3 mg

Indications

[Lymphatic filariasis](#) [Onchocerciasis](#)



Kanamycin [General information](#)

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to [gentamicin](#) for [Other specified conjunctivitis](#) Therapeutic equivalent to [gentamicin](#) for [Infectious blepharitis](#)



Kanamycin (injection) [General information](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Ketamine [General information](#)

Section

General anaesthetics and oxygen > Injectable medicines

- Parenteral > General injections > unspecified: 10 mg per mL in vial (as hydrochloride); 50 mg per mL in vial (as hydrochloride)

Indications

[Anaesthetics and therapeutic gases](#)



Ketoconazole [General information](#)

Section

Medicines for endocrine disorders

- Oral > Solid > tablet: 200 mg

Indications

[Cushing syndrome](#)



Lamivudine [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 150 mg tablet

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Lamivudine + nevirapine + zidovudine [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Lamivudine + tenofovir [General information](#)

Section

Fixed-dose combinations of antiretrovirals

Indications

Therapeutic equivalent to [emtricitabine + tenofovir](#) for [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#) Therapeutic equivalent to [emtricitabine + tenofovir](#) for [Contact with or exposure to human immunodeficiency virus](#)



Lamivudine + zidovudine [General information](#)

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Lamotrigine [General information](#)

Section

Antiseizure medicines

- Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)

Indications

[Epilepsy or seizures](#)



Latanoprost [General information](#)

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

- Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops

Indications

[Primary open-angle glaucoma](#)

Ledipasvir + sofosbuvir [General information](#)

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 90 mg + 400 mg tablet

Indications

[Chronic hepatitis C](#)

Lenalidomide [General information](#)

Section

Immunomodulators

- Oral > Solid: 25 mg

Indications

[Plasma cell myeloma](#)

Lenvatinib [General information](#)

Section

Targeted therapies

- Oral > Solid > capsule: 4 mg; 10 mg

Indications

[Renal cell carcinoma of kidney, except renal pelvis](#)

Letrozole [General information](#)

Section

Ovulation inducers

- Oral > Solid > dosage form: 2.5 mg

Indications

[Female infertility without specification whether primary or secondary](#)

Leuprorelin [General information](#)

Section

Hormones and antihormones

- Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe

Indications

[Malignant neoplasms of breast](#) [Malignant neoplasms of prostate](#)

Levamisole [General information](#)

Section

Intestinal anthelmintics

- Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)

Indications

[Ascariasis](#)

Levetiracetam [General information](#)

Section

Antiseizure medicines

- Oral > Liquid: 100 mg per mL
- Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg
- Parenteral > General injections > IV: 100 mg per mL in 5 mL ampoule or vial; 5 mg per mL in 100 mL bag; 10 mg per mL in 100 mL bag; 15 mg per mL in 100 mL bag

Indications

[Epilepsy or seizures](#) [Status epilepticus](#)

Levodopa [General information](#)

Section
Medicines for parkinsonism
◦ Oral > Solid: 250 mg

Indications
[Parkinson disease](#)



Levodopa + benserazide [General information](#)

Section
Medicines for parkinsonism

Indications
Therapeutic equivalent to [levodopa + carbidopa](#) for [Parkinson disease](#)



Levodopa + carbidopa [General information](#)

Section
Medicines for parkinsonism

◦ Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet

Indications
[Parkinson disease](#)



Levofloxacin [General information](#)

Section
Antituberculosis medicines

◦ Oral > Solid > dispersible tablet: 100 mg
◦ Oral > Solid > tablet: 250 mg; 500 mg; 750 mg

Indications
[Multi-drug resistant Mycobacterium tuberculosis](#)



Levonorgestrel [General information](#)

Section
Oral hormonal contraceptives
◦ Oral > Solid: 750 µg [2]; 1.5 mg [1]
◦ Oral > Solid: 30 µg

Indications
[Contact with health services for postcoital contraception](#) [Contact with health services for contraceptive management](#)

Section
Intrauterine devices
◦ Intrauterine system with reservoir containing 52 mg of levonorgestrel.

Indications
[Contact with health services for insertion of contraceptive device](#)



Levonorgestrel-releasing implant [General information](#)

Section
Implantable contraceptives
◦ Implant > Subdermal: 75 mg per rod (two-rods)

Indications
[Contact with health services for insertion of contraceptive device](#)



Levothyroxine [General information](#)

Section
Thyroid hormones and antithyroid medicines
◦ Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)

Indications
[Hypothyroidism](#)



Lidocaine [General information](#)

Section
Antiarrhythmic medicines
◦ Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)

Indications

[Ventricular tachyarrhythmia](#)

Section

Local anaesthetics

- Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution
- Parenteral > Locoregional injections > Other: 1% (hydrochloride); 2% (hydrochloride); 0.5% (hydrochloride)
- Local > Topical > unspecified: 2 to 4% (hydrochloride)

Indications

[Local anaesthetics](#)

Lidocaine + epinephrine [General information](#)

Section

Local anaesthetics

- Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine
- Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine

Indications

[Local anaesthetics](#)

Lindane [General information](#)

Section

Dermatological medicines > Scabicides and pediculicides

- Local > Topical > Cream: 1%
- Local > Topical > Lotion: 1%

Indications

[Scabies](#)

Linezolid [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 400 mg tablet; 600 mg tablet
- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 600 mg

Indications

[Other specified bacterial diseases Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 150 mg (scored)
- Oral > Solid > tablet: 600 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Liraglutide [General information](#)

Section

Medicines for endocrine disorders

- Parenteral > General injections > SC: 6 mg per mL in 3 mL pre-filled pen

Indications

[Obesity](#)

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for [Obesity](#) Therapeutic equivalent to [semaglutide](#) for [Type 2 diabetes mellitus](#)

Lisinopril + amlodipine [General information](#)

Section

Antihypertensive medicines

- Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg

Indications

[Essential hypertension](#)

Lisinopril + hydrochlorothiazide [General information](#)

Section

Antihypertensive medicines

- Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg

Indications

[Essential hypertension](#)

Lisocabtagene maraleucel [General information](#)

Section

Antineoplastics and supportive medicines

Indications

Therapeutic equivalent to [axicabtagene ciloleucel](#) for [Diffuse large B-cell lymphomas](#)

Lithium carbonate [General information](#)

Section

Medicines for bipolar disorders

- Oral > Solid: 300 mg

Indications

[Bipolar or related disorders](#)

Loperamide [General information](#)

Section

Medicines for other common symptoms in palliative care

- Oral > Solid > dosage form: 2 mg

Indications

[Palliative care](#)

Lopinavir + ritonavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable)
- Oral > Solid > dosage form: 40 mg + 10 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Loratadine [General information](#)

Section

Antiallergics and medicines used in anaphylaxis

- Oral > Liquid: 1 mg per mL
- Oral > Solid > tablet: 10 mg; 5 mg (chewable); 10 mg (chewable)

Indications

[Allergic or hypersensitivity conditions of unspecified type](#)

Lorazepam [General information](#)

Section

Antiseizure medicines

- Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule

Indications

[Status epilepticus](#)

Section

Medicines for anxiety disorders

Indications

Therapeutic equivalent to [diazepam](#) for [Anxiety](#)

Losartan [General information](#)

Section

Antihypertensive medicines

- Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet

Indications

[Essential hypertension](#)

Section

Medicines used in heart failure

- Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet

Indications

[Heart failure](#)



Lovastatin [General information](#)

Section

Lipid-lowering agents

Indications

Therapeutic equivalent to [simvastatin](#) for [Mixed hyperlipidaemia](#) Therapeutic equivalent to [simvastatin](#) for [Coronary atherosclerosis](#)



Magnesium sulfate [General information](#)

Section

Antiseizure medicines

- Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)
- Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)

Indications

[Severe pre-eclampsia Eclampsia](#)



Mannitol [General information](#)

Section

Diuretics

- Parenteral > General injections > IV: 10% solution; 20% solution

Indications

[Ocular hypertension Cerebral oedema](#)



Measles vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against measles alone](#)



Mebendazole [General information](#)

Section

Intestinal anthelmintics

- Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)

Indications

[Ascariasis Enterobiasis Trichuriasis Hookworm diseases](#)

Section

Cysticidal medicines

- Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)

Indications

[Other specified echinococcosis](#)



Medroxyprogesterone acetate [General information](#)

Section

Injectable hormonal contraceptives

- Parenteral > General injections > IM: 150 mg per mL in 1 mL vial
- Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single

dose injection delivery system

Indications

[Contact with health services for reasons associated with reproduction](#)

Section

Progestogens

- Oral > Solid: 5 mg

Indications

[Excessive menstruation with irregular cycle](#)

Mefloquine [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid: 250 mg tablet (hydrochloride)

Indications

[Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax](#)

Section

Antimalarial medicines > Medicines for chemoprophylaxis in travellers

- Oral > Solid > tablet: 250 mg (scored) (as hydrochloride)

Indications

[Malaria due to Plasmodium falciparum](#)

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Solid: 250 mg tablet (hydrochloride)

Indications

[Malaria due to Plasmodium falciparum](#)

Meglumine antimoniate [General information](#)

Section

Antileishmaniasis medicines

- Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule

Indications

[Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis](#)

Meglumine iotroxate [General information](#)

Section

Diagnostic agents > Radiocontrast media

- Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL

Indications

[X-ray contrast media, iodinated](#)

Melarsoprol [General information](#)

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

- Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)

Indications

[Gambiense trypanosomiasis Rhodesiense trypanosomiasis](#)

Melphalan [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial powder for injection
- Oral > Solid: 2 mg

Indications

[Plasma cell myeloma](#)

Meningococcal meningitis vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against single bacterial diseases](#)

**Mercaptopurine [General information](#)**

Section

Cytotoxic medicines

- Oral > Solid: 50 mg tablet
- Oral > Liquid: 20 mg per mL

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Lymphoid leukaemia, not elsewhere classified](#) [Acute myeloid leukaemia with recurrent genetic abnormalities](#) [Langerhans cell histiocytosis](#)

**Meropenem [General information](#)**

Section

Watch group antibiotics

- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

Second choice

[Peritonitis \(severe\)](#) [Peritoneal abscess \(severe\)](#) [Neutropenia \(high-risk\)](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

**Meropenem + vaborbactam [General information](#)**

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#) [Carbapenem resistant Acinetobacter baumannii](#)

**Mesalazine [General information](#)**

Section

Anti-inflammatory medicines

Indications

Therapeutic equivalent to [sulfasalazine](#) for [Crohn disease site](#) Therapeutic equivalent to [sulfasalazine](#) for [Ulcerative colitis](#)

**Mesna [General information](#)**

Section

Supportive medicines

- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
- Oral > Solid: 400 mg; 600 mg
- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule
- Oral > Solid > tablet: 400 mg; 600 mg
- Oral > Other: 600 mg
- Oral > Solid > tablet: 400 mg

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Other specified malignant neoplasms of the ovary](#) [Germ cell tumour of testis](#) [Osteosarcoma of bone and articular cartilage of other specified sites](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Rhabdomyosarcoma primary site](#)

**Metformin [General information](#)**

Section

Hypoglycaemic agents

- Oral > Solid: 500 mg (hydrochloride)

Indications

[Type 2 diabetes mellitus](#)



Methadone [General information](#)

Section

Medicines for opioid use disorders

- Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)

Indications

[Opioid dependence](#)

Section

Opioid analgesics

- Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 25 mg per 5 mL (methadone hydrochloride); 50 mg per 5 mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
- Oral > Solid > tablet: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)

Indications

[Chronic cancer pain](#)



Methimazole [General information](#)

Section

Thyroid hormones and antithyroid medicines

- Oral > Solid > tablet: 5 mg; 10 mg

Indications

[Thyrotoxicosis](#)



Methionine [General information](#)

Section

Antidotes and other substances used in poisonings > Specific

- Oral > Solid: 250 mg (DL)

Indications

[Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs](#)



Methotrexate [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
- Oral > Solid: 2.5 mg (as sodium salt)
- Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Burkitt lymphoma including Burkitt leukaemia Malignant trophoblastic neoplasms of placenta Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis](#)

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)

Indications

[Psoriasis of unspecified type](#)

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

- Oral > Solid > tablet: 2.5 mg (as sodium salt)

Indications

[Rheumatoid arthritis, serology unspecified](#)

Section

Immunomodulators for non-malignant disease

- Parenteral > General injections > SC: pre-filled syringe in multiple strengths

Indications

[Crohn disease site Psoriatic arthritis](#)

Section

Medicines for juvenile joint diseases
◦ Oral > Solid > tablet: 2.5 mg (as sodium salt)

Indications

[Juvenile idiopathic arthritis](#)

Methoxy polyethylene glycol-epoetin beta [General information](#)

Section

Antianaemia medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Anaemia due to chronic disease](#)

Methyldopa [General information](#)

Section

Antihypertensive medicines

◦ Oral > Solid: 250 mg

Indications

[Essential hypertension](#) [Gestational hypertension](#)

Methylergometrine [General information](#)

Section

Uterotonics

Indications

Therapeutic equivalent to [ergometrine](#) for [Postpartum haemorrhage](#)

Methylphenidate [General information](#)

Section

Medicines for mental and behavioural disorders

- Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 20 mg (hydrochloride); 18 mg extended-release (hydrochloride); 27 mg extended-release (hydrochloride); 36 mg extended-release (hydrochloride); 54 mg extended-release (hydrochloride); 72 mg extended-release (hydrochloride)
- Oral > Solid > capsule: 10 to 60 mg extended-release (hydrochloride)

Indications

[Attention deficit hyperactivity disorder](#)

Methylthioninium chloride [General information](#)

Section

Antidotes and other substances used in poisonings > Specific

◦ Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule

Indications

[Acquired methaemoglobinaemia](#)

Meticillin [General information](#)

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)

Metoclopramide [General information](#)

Section

Medicines for other common symptoms in palliative care

- Oral > Liquid: 5 mg per 5 mL
- Oral > Solid: 10 mg (hydrochloride)
- Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)

Indications

[Palliative care](#)

Section

Antiemetic medicines

- Oral > Liquid: 5 mg per 5 mL
- Oral > Solid: 10 mg (scored) (hydrochloride)
- Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)

Indications

[Nausea or vomiting](#)

Metoprolol [General information](#)

Section

Medicines used in heart failure

Indications

Therapeutic equivalent to [bisoprolol](#) for [Heart failure](#)

Section

Antianginal medicines

Indications

Therapeutic equivalent to [bisoprolol](#) for [Angina pectoris](#)

Section

Antihypertensive medicines

Indications

Therapeutic equivalent to [bisoprolol](#) for [Essential hypertension](#)

Section

Antiarrhythmic medicines

Indications

Therapeutic equivalent to [bisoprolol](#) for [Cardiac arrhythmia](#)

Metronidazole [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Oral > Solid: 200 to 500 mg tablet
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
- Local > Rectal > Suppository: 500 mg; 1 g
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
- Oral > Solid > tablet: 500 mg; 200 mg; 250 mg; 400 mg

Indications

First choice

[Trichomoniasis](#) [Intestinal infections due to Clostridioides difficile](#) [Necrotising fasciitis](#) co-prescribed with [cefazolin](#) [Other specified prophylactic measures](#) co-prescribed with [cefotaxime](#) [Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [cefotaxime](#) [Peritoneal abscess \(severe\)](#) co-prescribed with [cefotaxime](#) [Peritonitis \(mild-moderate\)](#) co-prescribed with [cefotaxime](#) [Peritonitis \(severe\)](#) co-prescribed with [ceftriaxone](#) [Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [ceftriaxone](#) [Peritoneal abscess \(severe\)](#) co-prescribed with [ceftriaxone](#) [Peritonitis \(mild-moderate\)](#) co-prescribed with [ceftriaxone](#) [Peritonitis \(severe\)](#)

Second choice

co-prescribed with [ciprofloxacin](#) [Peritoneal abscess \(mild-moderate\)](#) co-prescribed with [ciprofloxacin](#) [Peritonitis \(mild-moderate\)](#)

Other indications

[Bacterial infection of unspecified site](#)

Section

Antiamoebic and anti giardiasis medicines

- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Parenteral > General injections > unspecified: 500 mg in 100 mL vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

Indications

[Amoebiasis](#)

Micafungin [General information](#)

Section

Antifungal medicines

- Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection

Indications

[Systemic or invasive candidosis](#)



Miconazole [General information](#)

Section

Dermatological medicines > Antifungal medicines

- Local > Topical > Cream: 2% (nitrate)
- Local > Topical > Ointment: 2% (nitrate)

Indications

[Fungal infection of the skin](#)



Midazolam [General information](#)

Section

Antiseizure medicines

- Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial (for buccal administration); 5 mg per mL in 1 mL vial (for buccal administration); 5 mg per mL in 3 mL vial (for buccal administration)
- Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)

Indications

Therapeutic equivalent to [lorazepam](#) for [Status epilepticus Status epilepticus](#)

Section

Preoperative medication and sedation for short-term procedures

- Parenteral > General injections > IV: 1 mg per mL in 5 vial; 5 mg per mL in 1 mL vial; 5 mg per mL in 3 mL vial
- Oral > Liquid: 2 mg per mL
- Oral > Solid > dosage form: 15 mg; 7.5 mg

Indications

[Sedative-hypnotic and anxiolytic drugs](#)

Section

Medicines for other common symptoms in palliative care

- Oral > Liquid: 2 mg per mL
- Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial; 5 mg per mL in 1 mL vial; 5 mg per mL in 3 mL vial
- Local > Buccal > Solution: ; 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)
- Oral > Solid > dosage form: 7.5 mg; 15 mg

Indications

[Palliative care](#)



Mifepristone - misoprostol [General information](#)

Section

Medicines for medical abortion

- Oral > Solid > tablet: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package

Indications

[Unspecified time of fetal death, cause not specified Induced abortion](#)



Miltefosine [General information](#)

Section

Antileishmaniasis medicines

- Oral > Solid: 10 mg; 50 mg

Indications

[Visceral leishmaniasis Cutaneous leishmaniasis Mucocutaneous leishmaniasis](#)



Misoprostol [General information](#)

Section

Uterotonics

- Local > Vaginal > tablet: 25 µg
- Oral > Solid: 200 µg

Indications

[Unspecified obstetric condition Postpartum haemorrhage](#)

Section

Medicines for medical abortion

- Oral > Solid > tablet: 200 µg

Indications

[Spontaneous abortion, incomplete, without complication](#)



Mometasone [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [budesonide](#) for [Asthma](#)



Mometasone + formoterol [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [budesonide + formoterol](#) for [Asthma](#)



Morphine [General information](#)

Section

Opioid analgesics

- Oral > Liquid: 5 mg per 5 mL (morphine hydrochloride or morphine sulfate); 10 mg per 5 mL (morphine hydrochloride or morphine sulfate)
- Parenteral > General injections > unspecified: 1 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 2 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 10 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
- Oral > Solid > tablet: 10 mg immediate release (morphine sulfate)
- Oral > Solid > dosage form: 30 mg slow-release (morphine hydrochloride or morphine sulfate); 200 mg slow-release (morphine hydrochloride or morphine sulfate); 100 mg slow-release (morphine hydrochloride or morphine sulfate); 60 mg slow-release (morphine hydrochloride or morphine sulfate); 10 mg slow-release (morphine hydrochloride or morphine sulfate); 5 mg slow-release (morphine hydrochloride or morphine sulfate)
- Oral > Solid > granules: 20 mg (morphine sulfate); 30 mg (morphine sulfate); 60 mg (morphine sulfate); 100 mg (morphine sulfate); 200 mg (morphine sulfate)

Indications

[Pain](#)

Section

Preoperative medication and sedation for short-term procedures

- Parenteral > General injections > IV: 1 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 2 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 10 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate)

Indications

[Opioids or related analgesics and agents affecting opioid receptors](#)



Moxidectin [General information](#)

Section

Antifilarials

- Oral > Solid > tablet: 2 mg

Indications

Therapeutic equivalent to [ivermectin](#) for [Lymphatic filariasis](#) Therapeutic equivalent to [ivermectin](#) for [Onchocerciasis](#)



Moxifloxacin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > tablet: 400 mg
- Oral > Solid > dispersible tablet: 100 mg

Indications

[Tuberculosis Multi-drug resistant Mycobacterium tuberculosis](#)



Mpox vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against certain single viral diseases](#)



Multiple micronutrient supplement [General information](#)

Section

Other medicines administered to the mother

- Tablet containing:
 - Vit A: 800 mcg retinol activity equivalent
 - Vit C: 70 mg
 - Vit D: 5 mcg (200 IU)
 - Vit E: 10 mg alpha tocopherol equivalent
 - Vit B1: 1.4 mg
 - Vit B2: 1.4 mg
 - Vit B3: 18 mg niacin equivalent
 - Vit B6: 1.9 mg
 - Folic acid: 400 mcg
 - Vit B12: 2.6 mcg
 - Iron: 30 mg
 - Iodine: 150 mcg
 - Zinc: 15 mg
 - Selenium: 65 mcg
 - Copper: 2 mg

Indications

[Maternal care for other specified conditions predominantly related to pregnancy](#)



Mumps vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against mumps alone](#)



Mupirocin [General information](#)

Section

Dermatological medicines > Anti-infective medicines

- Local > Topical > Cream: 2% (as mupirocin calcium)
- Local > Topical > Ointment: 2%

Indications

[Superficial bacterial folliculitis Impetigo](#)



Nadroparin [General information](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [enoxaparin](#) for [Acute ischaemic heart disease](#) Therapeutic equivalent to [enoxaparin](#) for [Venous thromboembolism](#)



Nafcillin [General information](#)

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial](#)

[infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)



Nalidixic acid [General information](#)

Section

Anti-infective medicines

- Oral > Solid: 250 mg; 500 mg

Indications

[Shigella resistant to unspecified antibiotic](#)



Naloxone [General information](#)

Section

Antidotes and other substances used in poisonings > Specific

- Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)

Indications

[Unintentional exposure to or harmful effects of opioids or related analgesics](#)



Naltrexone [General information](#)

Section

Medicines for alcohol use disorders

- Parenteral > General injections > IM: 380 mg in vial (extended-release)
- Oral > Solid > tablet: 50 mg

Indications

[Disorders due to use of alcohol](#)



Naproxen [General information](#)

Section

Medicines for acute migraine attacks

Indications

Therapeutic equivalent to [ibuprofen](#) for [Migraine](#)



Natamycin [General information](#)

Section

Ophthalmological preparations > Anti-infective agents

- Local > Ophthalmological > Suspension: 5% eye drops

Indications

[Infectious keratitis](#)



Nelfinavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 250 mg (as mesilate)
- Oral > Other: 50 mg per g oral powder

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Neostigmine [General information](#)

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

- Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
- Oral > Solid > tablet: 15 mg (neostigmine bromide)

Indications

[Myasthenia gravis Anticholinesterase reversible](#)

Section

Medicines for myasthenia gravis

- Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
- Oral > Solid > tablet: 15 mg (neostigmine bromide)

Indications

[Myasthenia gravis](#)

Netilmicin [General information](#)

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to [gentamicin](#) for [Other specified conjunctivitis](#) Therapeutic equivalent to [gentamicin](#) for [Infectious blepharitis](#)

Nevirapine [General information](#)

Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid > dispersible tablet: 50 mg
- Oral > Solid > tablet: 200 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Niclosamide [General information](#)

Section

Intestinal anthelmintics

- Oral > Solid: 500 mg tablet (chewable)

Indications

[Hymenolepiasis](#) [Diphyllobothriasis](#) [Taeniasis due to Taenia saginata](#) [Taeniasis due to Taenia solium](#)

Nicotinamide [General information](#)

Section

Vitamins and minerals

- Oral > Solid: 50 mg

Indications

[Pellagra](#)

Nicotine replacement therapy [General information](#)

Section

Medicines for nicotine use disorders

- Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour
- Oral > Solid > lozenge: 2 mg; 4 mg lozenge
- Local > Buccal > Oral spray: 1 mg per actuation
- Local > Buccal > Chewing gum: 2 mg; 4 mg

Indications

[Nicotine dependence](#)

Nifedipine [General information](#)

Section

Antioxytocics (tocolytics)

- Oral > Solid: 10 mg (immediate-release)

Indications

[Preterm labour without delivery](#)

Section

Antianginal medicines

- Oral > Solid: 10 mg

Indications

[Angina pectoris](#)

Section

Antihypertensive medicines

- Oral > Solid: 10 mg tablet; sustained-release formulations

Indications

[Essential hypertension](#)

Nifurtimox [General information](#)

Section

American trypanosomiasis

- Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)

Indications

[Chagas disease](#)

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

- Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)

Indications

[Gambiense trypanosomiasis](#)



Nilotinib [General information](#)

Section

Targeted therapies

- Oral > Solid > capsule: 150 mg; 200 mg

Indications

[Chronic myeloid leukaemia, not elsewhere classified](#)



Nilutamide [General information](#)

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [bicalutamide](#) for [Malignant neoplasms of prostate](#)



Nitrofurantoin [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 25 mg per 5 mL oral liquid
- Oral > Solid > dosage form: 100 mg; 50 mg

Indications

First choice

[Infectious cystitis](#)



Nitrous oxide [General information](#)

Section

General anaesthetics and oxygen > Inhalational medicines

- Respiratory > Inhalation:

Indications

[Anaesthetics and therapeutic gases](#)



Nivolumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
- Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion
- Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion

Indications

Therapeutic equivalent to [pembrolizumab](#) for [Melanoma of skin Melanoma of skin Renal cell carcinoma of kidney, except renal pelvis Other specified malignant neoplasms of bronchus or lung Squamous cell carcinoma of oesophagus Adenocarcinoma of oesophagogastric junction Adenocarcinoma of stomach](#)



Norethisterone [General information](#)

Section

Oral hormonal contraceptives

- Oral > Solid: 350 µg

Indications

[Contact with health services for contraceptive management](#)

Section

Progestogens

- Oral > Solid: 5 mg

Indications

[Excessive menstruation with irregular cycle](#) Therapeutic equivalent to [medroxyprogesterone acetate](#) for [Excessive menstruation with irregular cycle](#)



Norethisterone enantate [General information](#)

Section

Injectable hormonal contraceptives

- Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution

Indications

[Contact with health services for reasons associated with reproduction](#)



Normal immunoglobulin [General information](#)

Section

Human immunoglobulins

- Parenteral > General injections > IV: 5% protein solution; 10% protein solution
- Parenteral > General injections > IM: 16% protein solution
- Parenteral > General injections > SC: 15% protein solution; 16% protein solution

Indications

[Primary immunodeficiencies Mucocutaneous lymph node syndrome Langerhans cell histiocytosis](#)

Section

Medicines for Guillain-Barré syndrome

- Parenteral > General injections > IV: 5% protein solution; 10% protein solution

Indications

[Acute inflammatory demyelinating polyneuropathy](#)



Nystatin [General information](#)

Section

Antifungal medicines

- Oral > Liquid: 100000 IU per mL
- Local > Topical > Other: 100000 IU pessary
- Oral > Solid > dosage form: 500000 IU
- Oral > Solid > lozenge: 100000 IU

Indications

[Candidosis](#)



Ocrelizumab [General information](#)

Section

Medicines for multiple sclerosis

- Parenteral > General injections > IV: 30 mg per mL in 10 mL vial
- Parenteral > General injections > IV: 30 mg per mL in 10 vial concentrate for solution

Indications

[Relapsing-remitting multiple sclerosis Multiple sclerosis](#)



Octreotide [General information](#)

Section

Medicines for disorders of the pituitary hormone system

- Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent
- Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)

Indications

[Acromegaly or pituitary gigantism](#)



Ofloxacin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 200 mg; 400 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Section

Ophthalmological preparations > Anti-infective agents

- Local > Ophthalmological > Solution (eye drops): 0.3%

Indications

[Other specified conjunctivitis Infectious keratitis](#)



Olanzapine [General information](#)

Section

Medicines for psychotic disorders

- Parenteral > General injections > IM: 10 mg in vial powder for injection

Indications

Therapeutic equivalent to [risperidone](#) for [Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders](#)



Omadacycline [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 100 mg lyophilized powder for injection
- Oral > Solid: 300 mg

Indications

[Methicillin resistant Staphylococcus aureus](#)



Ombitasvir + paritaprevir + ritonavir [General information](#)

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet

Indications

[Chronic hepatitis C](#)



Omeprazole [General information](#)

Section

Antiulcer medicines

- Parenteral > General injections > IV: 40 mg in vial
- Oral > Liquid: 1 mg per mL powder for oral liquid; 4 mg per mL powder for oral liquid
- Oral > Solid > dosage form: 10 mg; 20 mg; 40 mg

Indications

[Gastrointestinal bleeding Peptic ulcer, site unspecified Gastro-oesophageal reflux disease](#)



Ondansetron [General information](#)

Section

Medicines for other common symptoms in palliative care

- Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (as hydrochloride dihydrate); 2 mg per mL in 4 mL ampoule (as hydrochloride dihydrate)
- Oral > Liquid: 4 mg per 5 mL (as hydrochloride dihydrate)
- Oral > Solid: 4 mg (as hydrochloride dihydrate); 8 mg (as hydrochloride dihydrate)

Indications

[Palliative care](#)

Section

Antiemetic medicines

- Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (as hydrochloride dihydrate); 2 mg per mL in 4 mL ampoule
- Oral > Liquid: 4 mg per 5 mL (as hydrochloride dihydrate)
- Oral > Solid > dosage form: 4 mg (as hydrochloride dihydrate); 8 mg (as hydrochloride dihydrate); 24 mg (as hydrochloride dihydrate)

Indications

[Nausea or vomiting](#)



Oral rehydration salts [General information](#)

Section

Solutions correcting water, electrolyte and acid-base disturbances > Oral

- Powder for dilution in 200 mL, 500 mL, 1 L:
-
- - glucose 75 mEq or mmol/L
- - sodium 75 mEq or mmol/L
- - chloride 65 mEq or mmol/L
- - potassium 20 mEq or mmol/L
- - citrate 10 mEq or mmol/L
- - osmolarity 245 mOsm/L
- - glucose 13.5 g/L
- - sodium chloride 2.6 g/L
- - potassium chloride 1.5 g/L
- - trisodium citrate dihydrate 2.9 g/L

Indications

[Other specified disorders of fluid, electrolyte or acid-base balance](#)

Section

Oral rehydration

- Powder for dilution in 200 mL, 500 mL, 1 L:
-
- - glucose 75 mEq or mmol/L
- - sodium 75 mEq or mmol/L
- - chloride 65 mEq or mmol/L
- - potassium 20 mEq or mmol/L
- - citrate 10 mEq or mmol/L
- - osmolarity 245 mOsm/L
- - glucose 13.5 g/L
- - sodium chloride 2.6 g/L
- - potassium chloride 1.5 g/L
- - trisodium citrate dihydrate 2.9 g/L

Indications

[Diarrhoea](#)



Oseltamivir [General information](#)

Section

Other antivirals

- Oral > Liquid: 6 mg per mL (as phosphate) powder for oral liquid
- Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)

Indications

[Influenza due to identified seasonal influenza virus](#)



Osimertinib [General information](#)

Section

Targeted therapies

- Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)

Indications

[Other specified malignant neoplasms of bronchus or lung](#)



Oxacillin [General information](#)

Section

Access group antibiotics

Indications

First choice

Therapeutic equivalent to [cloxacillin](#) for [Osteomyelitis or osteitis](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial infection of joint](#) Therapeutic equivalent to [cloxacillin](#) for [Bacterial cellulitis, erysipelas or lymphangitis](#)



Oxaliplatin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial

Indications

[Malignant neoplasm metastasis in large intestine](#) [Malignant neoplasms of colon](#)

Oxamniquine [General information](#)

Section

Antischistosomes and other antitrematode medicines

- Oral > Liquid: 250 mg per 5 mL
- Oral > Solid > capsule: 250 mg

Indications

[Schistosomiasis due to Schistosoma mansoni](#)

Oxazolindinones [General information](#)

Section

Reserve group antibiotics

- .

Indications

[Other specified bacterial diseases](#)

Oxycodone [General information](#)

Section

Opioid analgesics

Indications

Therapeutic equivalent to [morphine](#) for [Pain](#)

Oxygen [General information](#)

Section

General anaesthetics and oxygen > Inhalational medicines

- Respiratory > Inhalation: (medical gas)

Indications

[Anaesthetics and therapeutic gases](#)

Section

Medical gases

- Respiratory > Inhalation:

Indications

[Respiratory failure as acute or chronic](#)

Oxytetracycline [General information](#)

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to [tetracycline](#) for [Other specified conjunctivitis](#) Therapeutic equivalent to [tetracycline](#) for [Infectious keratitis](#) Therapeutic equivalent to [tetracycline](#) for [Trachoma](#) Therapeutic equivalent to [tetracycline](#) for [Infectious blepharitis](#)

Oxytocin [General information](#)

Section

Uterotonics

- Parenteral > General injections > unspecified: 10 IU per mL

Indications

[Postpartum haemorrhage](#)

P-aminosalicylate sodium [General information](#)

Section

Antituberculosis medicines

- Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

P-aminosalicylic acid [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 4 g granules in sachet

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Paclitaxel [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 6 mg per mL

Indications

[Other specified malignant neoplasms of the ovary](#) [Other specified malignant neoplasms of bronchus or lung](#)
[Malignant neoplasms of nasopharynx](#) [Kaposi sarcoma of unspecified primary site](#) [Other specified malignant neoplasms of breast](#) [Other specified carcinomas of ovary](#) [Malignant neoplasms of breast](#) [Malignant neoplasms of cervix uteri](#)

Palbociclib [General information](#)

Section

Targeted therapies

- Oral > Solid: 75 mg; 100 mg; 125 mg

Indications

[Other specified malignant neoplasms of breast](#)

Paliperidone [General information](#)

Section

Medicines for psychotic disorders

- Parenteral > General injections > IM: 25 mg in pre-filled syringe (as palmitate); 50 mg in pre-filled syringe (as palmitate); 75 mg in pre-filled syringe (as palmitate); 100 mg in pre-filled syringe (as palmitate); 150 mg in pre-filled syringe (as palmitate)

Indications

Therapeutic equivalent to [risperidone](#) for [Schizophrenia or other primary psychotic disorders](#) [Schizophrenia or other primary psychotic disorders](#)

Palonosetron [General information](#)

Section

Medicines for other common symptoms in palliative care

Indications

Therapeutic equivalent to [ondansetron](#) for [Palliative care](#)

Section

Antiemetic medicines

Indications

Therapeutic equivalent to [ondansetron](#) for [Nausea or vomiting](#)

Panitumumab [General information](#)

Section

Targeted therapies

- Parenteral > General injections > IV: 20 mg per mL in 5 mL vial concentrate for solution for infusion; 20 mg per mL in 20 mL vial

Indications

[Other specified malignant neoplasms of large intestine](#)

Paracetamol (acetaminophen) [General information](#)

Section

Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)

- Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
- Local > Rectal > Suppository: 100 mg; 250 mg
- Oral > Solid > dispersible tablet: 100 mg; 250 mg
- Oral > Solid > tablet: 250 mg; 325 mg; 500 mg

Indications

[Pain](#)

Section

Medicines for acute migraine attacks

- Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
- Local > Rectal > Suppository: 250 mg
- Oral > Solid > dispersible tablet: 100 mg; 250 mg
- Oral > Solid > tablet: 250 mg; 325 mg; 500 mg

Indications

[Migraine](#)



Paromomycin [General information](#)

Section

Antileishmaniasis medicines

- Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)

Indications

[Visceral leishmaniasis](#)

Section

Antiamoebic and anti giardiasis medicines

- Oral > Liquid: 125 mg per 5 mL as sulfate
- Oral > Solid: 250 mg as sulfate

Indications

[Amoebiasis](#)



Pegaspargase [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection

Indications

[Lymphoid leukaemia, not elsewhere classified](#)



Pegfilgrastim [General information](#)

Section

Immunomodulators

- Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe

Indications

[Acquired neutropaenia](#)



Pegylated interferon alfa (2a) [General information](#)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

- Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe

Indications

[Chronic hepatitis C](#)



Pegylated interferon alfa (2b) [General information](#)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

- Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe

Indications

[Chronic hepatitis C](#)



Pembrolizumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial
- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection
- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion

Indications

[Melanoma of skin](#) [Other specified malignant neoplasms of large intestine](#) [Malignant neoplasms of cervix uteri](#) [Other specified malignant neoplasms of bronchus or lung](#) [Adenocarcinoma of stomach](#) [Malignant neoplasms of oesophagogastric junction](#) [Squamous cell carcinoma of hypopharynx and variants](#) [Squamous cell carcinoma of](#)

[other or ill-defined sites in the lip, oral cavity or pharynx](#) [Squamous cell carcinoma of oropharynx](#) [Squamous cell carcinoma of nasopharynx](#) Therapeutic equivalent to [nivolumab](#) for [Melanoma of skin](#) [Renal cell carcinoma of kidney, except renal pelvis](#) [Carcinoma of breast, specialised type](#) [Squamous cell carcinoma of oesophagus](#)

Penicillamine [General information](#)

Section

Antidotes and other substances used in poisonings > Specific

- Oral > Solid: 250 mg

Indications

[Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified](#)

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

- Oral > Solid: 250 mg

Indications

[Rheumatoid arthritis, serology unspecified](#)

Pentamidine [General information](#)

Section

Antileishmaniasis medicines

- Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)

Indications

[Visceral leishmaniasis](#)

Section

Medicines for the treatment of 1st stage African trypanosomiasis

- Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection

Indications

[Gambiense trypanosomiasis](#)

Section

Antipneumocystosis and antitoxoplasmosis medicines

- Oral > Solid > tablet: 200 mg (as isethionate); 300 mg (as isethionate)

Indications

[Pneumocystosis](#)

Perindopril + amlodipine + indapamide [General information](#)

Section

Antihypertensive medicines

- Oral > Solid > dosage form: 5 mg (arginine) + 5 mg + 1.25 mg; 5 mg (arginine) + 10 mg + 1.25 mg; 10 mg (arginine) + 5 mg + 2.5 mg; 10 mg (arginine) + 10 mg + 2.5 mg

Indications

[Essential hypertension](#)

Permethrin [General information](#)

Section

Dermatological medicines > Scabicides and pediculicides

- Local > Topical > Lotion: 1%
- Local > Topical > Cream: 5%

Indications

[Pediculosis corporis](#) [Pediculosis capitis](#) [Scabies](#)

Pertussis vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against pertussis alone](#)

Pertuzumab [General information](#)

Section

Targeted therapies

- Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution

Indications

[Carcinoma of breast, specialised type](#)



Phenelzine [General information](#)

Section

Medicines for depressive disorders

- Oral > Solid > dosage form: 15 mg (as sulfate)

Indications

[Other specified depressive disorders](#)



Phenobarbital [General information](#)

Section

Antiseizure medicines

- Parenteral > General injections > IV: 200 mg per mL (phenobarbital sodium); 30 mg per mL (phenobarbital sodium); 60 mg per mL (phenobarbital sodium)
- Oral > Liquid: 15 mg per 5 mL
- Oral > Solid > tablet: 15 mg; 30 mg; 60 mg; 100 mg

Indications

[Status epilepticus Epilepsy or seizures](#)



Phenoxyethylpenicillin [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
- Oral > Solid: 250 mg (as potassium salt) tablet
- Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)

Indications

First choice

[Bacterial pneumonia \(Community-acquired pneumonia - mild to moderate\) Periapical abscess without sinus Acute pharyngitis](#)

Other indications

[Bacterial infection of unspecified site](#)



Phenytoin [General information](#)

Section

Antiseizure medicines

- Oral > Liquid: 30 mg per 5 mL (phenytoin)
- Parenteral > General injections > unspecified: 50 mg per mL in vial (phenytoin sodium)
- Oral > Solid > tablet: 50 mg (phenytoin) (chewable)
- Oral > Solid > dosage form: 25 mg (phenytoin sodium); 50 mg (phenytoin sodium); 100 mg (phenytoin sodium)

Indications

[Epilepsy or seizures](#)



Phosphorus [General information](#)

Section

Medicines for endocrine disorders

- Oral > Other: 500 mg in sachet (elemental phosphorus) granules
- Oral > Solid > tablet: 250 mg (elemental phosphorus); 500 mg (elemental phosphorus); 500 mg (elemental phosphorus) (effervescent)

Indications

[Hypophosphataemic rickets](#)



Phytomenadione [General information](#)

Section

Medicines affecting coagulation

- Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule; 2 mg per 0.2 mL in ampoule mixed micelle solution; 10 mg per mL in ampoule mixed micelle solution; 1 mg per 0.5 mL in ampoule
- Oral > Solid > tablet: 5 mg tablet

Indications

[Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors](#)

Pilocarpine [General information](#)

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

- Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)

Indications

[Acute angle closure with pupillary block](#) [Ocular hypertension](#) [Primary open-angle glaucoma](#)

Piperacillin + tazobactam [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

Indications

First choice

[Neutropenia \(high-risk\)](#) [Other specified pneumonia \(Hospital-acquired pneumonia\)](#) [Peritonitis \(severe\)](#) [Peritoneal abscess \(severe\)](#) co-prescribed with [clindamycin](#) [Necrotising fasciitis](#)

Platelets [General information](#)

Section

Blood and blood components

- Parenteral > General injections > IV:

Indications

[Blood transfusion without reported diagnosis](#)

Plazomicin [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500 mg per 10 mL

Indications

[Carbapenem resistant Acinetobacter baumannii](#) [Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#)

Pneumococcal vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against single bacterial diseases](#)

Podophyllotoxin [General information](#)

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to [podophyllum resin](#) for [Plantar warts](#) Therapeutic equivalent to [podophyllum resin](#) for [Anogenital warts](#)

Podophyllum resin [General information](#)

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Local > Topical > Solution: 10 to 25%

Indications

[Plantar warts](#) [Anogenital warts](#)

Poliomyelitis vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against poliomyelitis](#)

Polygeline [General information](#)

Section

Plasma substitutes

- Parenteral > General injections > IV: 3.5% injectable solution
- Parenteral > General injections > IV: 3.5% in solution

Indications

Therapeutic equivalent to [dextran 70](#) for [Hypovolaemia Hypovolaemia](#)

Polymyxin B (injection) [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)

Indications

[Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales Carbapenem resistant Acinetobacter baumannii](#)

Polymyxins [General information](#)

Section

Reserve group antibiotics

- .

Indications

[Other specified bacterial diseases](#)

Potassium chloride [General information](#)

Section

Solutions correcting water, electrolyte and acid-base disturbances > Parenteral

- Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K⁺ 1.5 mmol/mL and Cl⁻ 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K⁺ 1 mmol/mL and Cl⁻ 2 mmol/mL); 15% solution for dilution (equivalent to K⁺ 2 mmol/mL and Cl⁻ 2 mmol/mL)

Indications

[Hypokalaemia](#)

Section

Solutions correcting water, electrolyte and acid-base disturbances > Oral

- Oral > Liquid: powder for solution

Indications

[Hypokalaemia](#)

Potassium ferric hexacyanoferrate (Prussian blue) [General information](#)

Section

Antidotes and other substances used in poisonings > Specific

- Oral > Solid: Powder for oral administration

Indications

[Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified](#)

Potassium iodide [General information](#)

Section

Antifungal medicines

- Local > Topical > Solution: Saturated solution

Indications

[Sporotrichosis](#)

Section

Thyroid hormones and antithyroid medicines

- Oral > Solid > tablet: 65 mg (scored)

Indications

[Thyrotoxicosis](#)

Potassium permanganate [General information](#)

Section

Dermatological medicines > Anti-infective medicines

- Local > Topical > Solution: aqueous solution: 1:10 000

Indications

[Tropical phagedaenic ulcer Pemphigus Impetigo Other specified pyogenic bacterial infection of skin and subcutaneous tissue](#)

Povidone iodine [General information](#)

Section

Antiseptics

- Local > Topical > Solution: 10% (equivalent to 1% available iodine)

Indications

[Povidone iodine](#)

Pralidoxime [General information](#)

Section

Antidotes and other substances used in poisonings > Specific

- .

Indications

[Exposure to or harmful effects of undetermined intent of pesticides](#)

Pramipexole [General information](#)

Section

Medicines for central nervous system disorders

- Oral > Solid: 125 µg immediate-release; 250 mg immediate-release; 500 µg immediate-release; 750 µg immediate-release; 1 mg immediate-release; 1.5 mg immediate-release; 375 µg extended-release; 750 µg extended-release; 1.5 mg extended-release; 2.25 mg extended-release; 3 mg extended-release; 3.75 mg extended-release; 4.5 extended-release

Indications

[Parkinson disease](#)

Pravastatin [General information](#)

Section

Lipid-lowering agents

Indications

Therapeutic equivalent to [simvastatin](#) for [Mixed hyperlipidaemia](#) Therapeutic equivalent to [simvastatin](#) for [Coronary atherosclerosis](#)

Praziquantel [General information](#)

Section

Cysticidal medicines

- Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Indications

[Cysticercosis of central nervous system](#)

Section

Antischistosomes and other antitrematode medicines

- Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Indications

[Paragonimiasis Clonorchiasis Opisthorchiasis Schistosomiasis](#)

Section

Intestinal anthelmintics

- Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Indications

[Diphyllobothriasis Taeniasis due to Taenia saginata Taeniasis due to Taenia solium Hymenolepiasis](#)

Precipitated sulfur [General information](#)

Section

Dermatological medicines > Scabicides and pediculicides

- Local > Topical > Ointment:

Indications

Therapeutic equivalent to [benzyl benzoate](#) for [Pediculosis corporis](#) Therapeutic equivalent to [benzyl benzoate](#) for [Pediculosis capitis](#) Therapeutic equivalent to [benzyl benzoate](#) for [Scabies](#) Therapeutic equivalent to [benzyl benzoate](#) for [Pthiriasis](#)



Prednisolone [General information](#)

Section

Hormones and antihormones

- Oral > Liquid: 5 mg per mL
- Oral > Solid: 5 mg; 25 mg

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Follicular lymphoma](#) [Lymphoid leukaemia, not elsewhere classified](#) [Diffuse large B-cell lymphoma, not otherwise specified](#) [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#) [Hodgkin lymphoma](#) [Plasma cell myeloma](#) [Malignant neoplasms of prostate](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#) [Langerhans cell histiocytosis](#)

Section

Anti-inflammatory medicines

- Local > Rectal > Retention enema:
- Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)

Indications

Therapeutic equivalent to [hydrocortisone](#) for [Crohn disease site](#) [Crohn disease site](#) [Ulcerative colitis](#)

Section

Antiallergics and medicines used in anaphylaxis

- Oral > Liquid: 5 mg per mL
- Oral > Solid: 5 mg; 25 mg

Indications

[Allergic or hypersensitivity conditions of unspecified type](#)

Section

Ophthalmological preparations > Anti-inflammatory agents

- Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)

Indications

[Scleritis](#) [Anterior uveitis](#)

Section

Adrenal hormones and synthetic substitutes

- Oral > Solid > tablet: 1 mg

Indications

[Adrenocortical insufficiency](#)

Section

Medicines for cluster headache

- Oral > Solid > tablet: 5 mg; 25 mg

Indications

[Trigeminal autonomic cephalalgias](#)



Prednisone [General information](#)

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [prednisolone](#) for [Follicular lymphoma](#) Therapeutic equivalent to [prednisolone](#) for [Lymphoid leukaemia, not elsewhere classified](#) Therapeutic equivalent to [prednisolone](#) for [Diffuse large B-cell lymphoma, not otherwise specified](#) Therapeutic equivalent to [prednisolone](#) for [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#) Therapeutic equivalent to [prednisolone](#) for [Hodgkin lymphoma](#) Therapeutic equivalent to [prednisolone](#) for [Plasma cell myeloma](#) Therapeutic equivalent to [prednisolone](#) for [Malignant neoplasms of prostate](#) Therapeutic equivalent to [prednisolone](#) for [Anaplastic large cell lymphoma, ALK-negative](#) Therapeutic equivalent to [prednisolone](#) for [Anaplastic large cell lymphoma, ALK-positive](#) Therapeutic equivalent to [prednisolone](#) for [Langerhans cell histiocytosis](#)

Section

Antiallergics and medicines used in anaphylaxis

Indications

Therapeutic equivalent to [prednisolone](#) for [Allergic or hypersensitivity conditions of unspecified type](#)

Section

Adrenal hormones and synthetic substitutes

- Oral > Solid > tablet: 1 mg

Indications

Therapeutic equivalent to [prednisolone](#) for [Adrenocortical insufficiency](#)

Pretomanid [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > tablet: 200 mg

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)

Primaquine [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid > tablet: 7.5 mg (as phosphate); 15 mg (as phosphate)

Indications

[Malaria due to Plasmodium ovale](#) [Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)

Probenecid [General information](#)

Section

Medicines used to treat gout

- Oral > Solid: 500 mg

Indications

[Gout](#)

Procainamide [General information](#)

Section

Antiarrhythmic medicines

- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule (hydrochloride)
- Oral > Solid: 500 mg (hydrochloride); 250 mg (hydrochloride)

Indications

[Cardiac arrhythmia](#)

Procaine benzylpenicillin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection

Indications

Second choice

[Syphilis](#)

Procarbazine [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 50 mg (as hydrochloride)

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Progesterone vaginal ring [General information](#)

Section

Intravaginal contraceptives

- Local > Vaginal > vaginal ring: 2.074 g micronized progesterone

Indications

[Contact with health services for contraceptive management](#)

Proguanil [General information](#)

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Solid: 100 mg tablet (hydrochloride)

Indications

[Malaria due to Plasmodium falciparum](#)

Promethazine [General information](#)

Section

Antiemetic medicines

- Oral > Liquid: 5 mg per 5 mL (hydrochloride)
- Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
- Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule

Indications

[Nausea or vomiting](#)

Propranolol [General information](#)

Section

Antiseptics

Indications

Therapeutic equivalent to [ethanol](#) for [Denatured alcohol](#)

Propofol [General information](#)

Section

General anaesthetics and oxygen > Injectable medicines

- Parenteral > General injections > IV: 10 mg per mL; 20 mg per mL

Indications

[Anaesthetics and therapeutic gases](#)

Propranolol [General information](#)

Section

Antianginal medicines

- Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)
- Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)

Indications

[Angina pectoris](#)

Section

Antiarrhythmic medicines

- Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)
- Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)

Indications

[Cardiac arrhythmia](#)

Section

Antihypertensive medicines

- Oral > Solid: 80 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)

Indications

[Essential hypertension](#)

Section

Medicines for migraine prophylaxis

- Oral > Solid > tablet: 40 mg (hydrochloride); 10 mg (hydrochloride)

Indications

[Migraine](#)

Propylthiouracil [General information](#)

Section

Thyroid hormones and antithyroid medicines

- Oral > Solid: 50 mg

Indications

[Thyrotoxicosis](#)

Protamine sulfate [General information](#)

Section

Medicines affecting coagulation

- Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule or vial

Indications

[Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors](#)

Protionamide [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > tablet: 250 mg (scored)

Indications

Therapeutic equivalent to [ethionamide](#) for [Multi-drug resistant Mycobacterium tuberculosis](#)

Pyrantel [General information](#)

Section

Intestinal anthelmintics

- Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)

Indications

[Ascariasis Enterobiasis Trichuriasis Hookworm diseases](#)

Pyrazinamide [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 400 mg; 500 mg

Indications

[Tuberculosis](#)

Pyridostigmine [General information](#)

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

- Parenteral > General injections > IV: 5 mg per mL in ampoule or vial (pyridostigmine bromide)
- Oral > Solid > tablet: 60 mg scored (pyridostigmine bromide)

Indications

[Myasthenia gravis](#)

Section

Medicines for myasthenia gravis

- Parenteral > General injections > IV: 5 mg per mL in ampoule or vial (pyridostigmine bromide)
- Oral > Solid > tablet: 60 mg scored (pyridostigmine bromide)

Indications

[Myasthenia gravis](#)

Pyridoxine [General information](#)

Section

Vitamins and minerals

- Oral > Solid > tablet: 25 mg (hydrochloride); 10 mg (hydrochloride)

Indications

[Other specified polyneuropathy Vitamin B6 deficiency Sideroblastic anaemia](#)

Pyrimethamine [General information](#)

Section

Antipneumocystosis and antitoxoplasmosis medicines

- Oral > Solid: 25 mg

Indications

[Toxoplasmosis](#)

Quetiapine [General information](#)

Section

Medicines for psychotic disorders

Indications

Therapeutic equivalent to [risperidone](#) for [Schizophrenia or other primary psychotic disorders](#)

Section

Medicines for bipolar disorders

- Oral > Solid > tablet: 25 mg (immediate-release); 100 mg (immediate-release); 150 mg (immediate-release); 200 mg (immediate-release); 300 mg (immediate-release); 50 mg (modified-release); 150 mg (modified-release); 200 mg (modified-release); 300 mg (modified-release); 400 mg (modified-release)

Indications

[Bipolar or related disorders](#)

Quinidine [General information](#)

Section

Antiarrhythmic medicines

- Oral > Solid: 200 mg (sulfate)

Indications

[Cardiac arrhythmia](#)

Quinine [General information](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion; 60 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion

Indications

[Malaria due to Plasmodium falciparum](#)

Rabies vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against rabies](#)

Raltegravir [General information](#)

Section

Antiretrovirals > Integrase inhibitors

- Oral > Liquid: 100 mg granules for oral suspension
- Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Ranibizumab [General information](#)

Section

Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

- .

Indications

[Retinal venous occlusions Diabetic macular oedema Age related macular degeneration Degenerative high myopia](#)

Ranitidine [General information](#)

Section

Antiulcer medicines

- Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride)
- Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)

Indications

[Peptic ulcer, site unspecified Gastro-oesophageal reflux disease](#)

Rasburicase [General information](#)

Section

Supportive medicines

- Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution

Indications

[Tumour lysis syndrome](#)

Ravidasvir [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg

Indications

[Chronic hepatitis C](#)

Realgar-indigo naturalis formulation [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)

Indications

[Acute myeloid leukaemia with recurrent genetic abnormalities](#)

Red blood cells [General information](#)

Section

Blood and blood components

- Parenteral > General injections > IV:

Indications

[Blood transfusion without reported diagnosis](#)

Resin-based composite (high-viscosity) [General information](#)

Section

Dental medicines and preparations

- Local > Topical > Other: Single-use capsule or multi-use syringe

Indications

[Dental caries](#)

Resin-based composite (low-viscosity) [General information](#)

Section

Dental medicines and preparations

- Local > Topical > Other: Single-use applicator or multi-use bottle

Indications

[Dental caries](#)

Respiratory syncytial virus vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against certain single viral diseases](#)

Retinol [General information](#)

Section

Vitamins and minerals

- Parenteral > General injections > IM: 50000 IU per mL in 2 mL ampoule or vial water-miscible (as palmitate)
- Oral > Liquid: 100000 IU per mL (as palmitate or acetate)
- Oral > Solid > capsule: 200000 IU (as palmitate or acetate) soft capsule; 50000 IU (as palmitate); 100000 IU (as palmitate or acetate) soft capsule

Indications

[Vitamin A deficiency](#)

Ribavirin [General information](#)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

- Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
- Oral > Solid: 200 mg; 400 mg; 600 mg

Indications

[Chronic hepatitis C](#)

Section

Other antivirals

- Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
- Oral > Solid: 200 mg; 400 mg; 600 mg

Indications

[Viral haemorrhagic fever, not elsewhere classified](#)

Ribociclib [General information](#)

Section

Targeted therapies

Indications

Therapeutic equivalent to [palbociclib](#) for [Other specified malignant neoplasms of breast](#)

Riboflavin [General information](#)

Section

Vitamins and minerals

- Oral > Solid: 5 mg

Indications

[Vitamin B2 deficiency](#)

Rifabutin [General information](#)

Section

Antituberculosis medicines

- Oral > Solid: 150 mg

Indications

[Tuberculosis](#)

Rifampicin [General information](#)

Section

Antituberculosis medicines

- Oral > Liquid: 20 mg per mL
- Oral > Solid: 150 mg; 300 mg
- Parenteral > General injections > IV: 600 mg in vial powder for injection

Indications

[Tuberculosis](#) [Other specified tuberculosis](#)

Section

Antileprosy medicines

- Oral > Liquid: 20 mg per mL
- Oral > Solid: 150 mg; 300 mg

Indications

[Leprosy](#)

Rifapentine [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > tablet: 150 mg; 300 mg
- Oral > Solid > dispersible tablet: 150 mg

Indications

[Tuberculosis](#) [Latent tuberculosis](#)

Risdiplam [General information](#)

Section

Medicines for neurological disorders

- Oral > Liquid: 0.75 mg per mL powder for oral liquid
- Oral > Solid > dispersible tablet: 5 mg

Indications

[Spinal muscular atrophy](#)



Risperidone [General information](#)

Section

Medicines for psychotic disorders

- Oral > Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg
- Parenteral > General injections > IM:

Indications

[Schizophrenia or other primary psychotic disorders](#) Therapeutic equivalent to [paliperidone](#) for [Schizophrenia or other primary psychotic disorders](#)



Ritonavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Rituximab [General information](#)

Section

Targeted therapies

- Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

Indications

[Follicular lymphoma Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Burkitt lymphoma including Burkitt leukaemia](#)

Section

Medicines for multiple sclerosis

- Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial

Indications

[Multiple sclerosis](#)



Rivaroxaban [General information](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) for [Other specified atrial fibrillation](#) Therapeutic equivalent to [dabigatran](#) for [Venous thromboembolism](#)



Ropinirole [General information](#)

Section

Medicines for central nervous system disorders

- Oral > Solid: 0.25 mg immediate-release; 0.5 mg immediate-release; 1 mg immediate-release; 2 immediate-release; 3 mg immediate-release; 4 mg immediate-release; 5 mg immediate-release; 2 mg extended-release; 4 mg extended-release; 6 mg extended-release; 8 mg extended-release; 12 mg extended-release

Indications

[Parkinson disease](#)



Rotavirus vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against certain single viral diseases](#)



Rubella vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against rubella alone](#)



Salbutamol [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

- Parenteral > General injections > IV: 500 µg per mL in 1 mL ampoule (as sulfate); 500 µg per mL in 5 mL ampoule (as sulfate)
- Respiratory > Inhalation > solution: 100 µg per actuation in pressurized metered dose inhaler (as sulfate); 2.5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers; 5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers; 5 mg per mL in multi-dose bottle (as sulfate) for use in nebulizers

Indications

[Chronic obstructive pulmonary disease Asthma](#)



Salicylic acid [General information](#)

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Local > Topical > Solution: 5%

Indications

[Seborrhoeic dermatitis Psoriasis of unspecified type Ichthyoses](#)



Saquinavir [General information](#)

Section

Antiretrovirals > Protease inhibitors

- Oral > Solid: 200 mg; 500 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Selenium sulfide [General information](#)

Section

Dermatological medicines > Antifungal medicines

- Local > Topical > Suspension: 2% detergent-based

Indications

[Seborrhoeic dermatitis Pityriasis versicolor](#)



Semaglutide [General information](#)

Section

Hypoglycaemic agents

- Parenteral > General injections > SC: 0.25 mg in pre-filled pen injection solution; 0.5 mg in pre-filled pen injection solution; 1 mg in pre-filled pen injection solution; 2 mg in pre-filled pen injection solution; 4 mg in pre-filled pen injection solution
- Oral > Solid > tablet: 3 mg
- Parenteral > General injections > SC: 0.68 mg per mL; 1.34 mg per mL; 2.68 mg per mL

Indications

[Obesity Type 2 diabetes mellitus](#)



Senna [General information](#)

Section

Medicines for other common symptoms in palliative care

- Oral > Liquid: 7.5 mg per 5 mL oral liquid

Indications

[Palliative care](#)

Section

Laxatives

- Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)

Indications

[Constipation](#)

Sevoflurane [General information](#)

Section

General anaesthetics and oxygen > Inhalational medicines

- Respiratory > Inhalation > liquid:

Indications

[Anaesthetics and therapeutic gases](#)

Silver diamine fluoride [General information](#)

Section

Dental medicines and preparations

- Local > Dental > Solution: 38% w/v

Indications

[Dental caries](#)

Silver nitrate [General information](#)

Section

Ophthalmological preparations > Anti-infective agents

- Local > Ophthalmological > Solution (eye drops): 1%

Indications

[Neonatal conjunctivitis or dacryocystitis](#)

Silver sulfadiazine [General information](#)

Section

Dermatological medicines > Anti-infective medicines

- Local > Topical > Cream: 1%

Indications

[Burns](#)

Simeprevir [General information](#)

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 150 mg

Indications

[Chronic hepatitis C](#)

Simvastatin [General information](#)

Section

Lipid-lowering agents

- Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg

Indications

[Mixed hyperlipidaemia Coronary atherosclerosis](#)

Section

Medicines for endocrine disorders

- Oral > Solid: 20 mg

Indications

[Polycystic ovary syndrome](#)

Smallpox vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against certain single viral diseases](#)

Snake antivenom [General information](#)

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

◦ .

Indications

[Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified](#)

Sodium calcium edetate [General information](#)

Section

Antidotes and other substances used in poisonings > Specific

◦ Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule

Indications

[Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified](#)

Sodium chloride [General information](#)

Section

Solutions correcting water, electrolyte and acid-base disturbances > Parenteral

◦ Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na⁺ 154 mmol/L and Cl⁻ 154 mmol/L)

Indications

[Other specified disorders of fluid, electrolyte or acid-base balance](#)

Sodium hyaluronate [General information](#)

Section

Ophthalmological preparations

Indications

Therapeutic equivalent to [hypromellose](#) for [Keratoconjunctivitis sicca](#)

Sodium hydrogen carbonate [General information](#)

Section

Solutions correcting water, electrolyte and acid-base disturbances > Parenteral

◦ Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na⁺ 167 mmol/L and HCO₃⁻ 167 mmol/L);
8.4% in 10 mL ampoule (equivalent to Na⁺ 1000 mmol/L and HCO₃⁻ 1000 mmol/L)

Indications

[Acidosis](#)

Sodium nitrite [General information](#)

Section

Antidotes and other substances used in poisonings > Specific

◦ Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule

Indications

[Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified](#)

Sodium nitroprusside [General information](#)

Section

Antihypertensive medicines

◦ Parenteral > General injections > IV: 50 mg in ampoule powder for infusion

Indications

[Hypertensive crisis](#)

Sodium stibogluconate [General information](#)

Section

Antileishmaniasis medicines

◦ Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial

Indications

[Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis](#)

Sodium thiosulfate [General information](#)

Section

Dermatological medicines > Antifungal medicines

- Local > Topical > Solution: 15%

Indications

[Pityriasis versicolor](#)

Section

Antidotes and other substances used in poisonings > Specific

- Parenteral > General injections > IV: 250 mg per mL in 50 mL ampoule

Indications

[Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified](#)



Sofosbuvir [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg; 400 mg
- Oral > Solid > granules: 200 mg in sachet

Indications

[Chronic hepatitis C](#)



Sofosbuvir + velpatasvir [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg
- Oral > Solid > granules: 150 mg + 37.5 mg in sachet; 200 mg + 50 mg in sachet

Indications

[Chronic hepatitis C](#)



Spectinomycin [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection

Indications

Second choice

[Gonococcal infection](#)

Other indications

[Bacterial infection of unspecified site](#)



Spirolactone [General information](#)

Section

Medicines used in heart failure

- Oral > Solid > tablet: 25 mg

Indications

[Heart failure](#)

Section

Diuretics

- Oral > Liquid: 25 mg per 5 mL
- Oral > Solid > tablet: 25 mg; 12.5 mg

Indications

[Oedema Ascites](#)



Stavudine [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 5 mg per 5 mL powder for oral solution
- Oral > Solid: 15 mg; 20 mg; 30 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Streptokinase [General information](#)

Section

Thrombolytic medicines

- Parenteral > General injections > IV: 1.5 million IU in vial powder for injection

Indications

[Acute myocardial infarction](#)



Streptomycin (injection) [General information](#)

Section

Antituberculosis medicines

- Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)



Succimer [General information](#)

Section

Antidotes and other substances used in poisonings > Specific

- Oral > Solid: 100 mg

Indications

[Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified](#)



Sulfacetamide [General information](#)

Section

Ophthalmological preparations > Anti-infective agents

- Local > Ophthalmological > Ointment: 10% (sodium salt)

Indications

[Other specified conjunctivitis](#)



Sulfadiazine [General information](#)

Section

Antipneumocystosis and antitoxoplasmosis medicines

- Oral > Solid: 500 mg

Indications

[Toxoplasmosis](#)

Section

Anti-infective medicines

- Oral > Solid: 500 mg
- Parenteral > General injections > unspecified: 250 mg in 4 mL ampoule (sodium salt)

Indications

[Bacterial infection of unspecified site](#)



Sulfadimidine [General information](#)

Section

Anti-infective medicines

- Oral > Liquid: 500 mg per 5 mL
- Oral > Solid: 500 mg
- Parenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt)

Indications

[Bacterial infection of unspecified site](#)



Sulfadoxine + pyrimethamine [General information](#)

Section

Antimalarial medicines > Medicines for chemoprevention

- Oral > Solid: 500 mg + 25 mg tablet

Indications

[Malaria due to Plasmodium falciparum](#)

Section

Antimalarial medicines > Medicines for curative treatment

- Oral > Solid: 500 mg + 25 mg tablet

Indications

[Malaria due to Plasmodium falciparum](#) [Malaria due to Plasmodium vivax](#)



Sulfamethoxazole + trimethoprim [General information](#)

Section

Access group antibiotics

- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
- Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
- Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
- Oral > Solid > dispersible tablet: 100 mg + 20 mg

Indications

First choice

[Infectious cystitis](#)

Second choice

[Infectious gastroenteritis or colitis without specification of infectious agent](#)

Other indications

[Bacterial infection of unspecified site](#)

Section

Antipneumocystosis and antitoxoplasmosis medicines

- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
- Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
- Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
- Oral > Solid > dispersible tablet: 100 mg + 20 mg

Indications

[Pneumocystosis](#)



Sulfasalazine [General information](#)

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

- Oral > Solid: 500 mg

Indications

[Rheumatoid arthritis, serology unspecified](#)

Section

Anti-inflammatory medicines

- Oral > Solid: 500 mg
- Local > Rectal > Suppository: 500 mg
- Local > Rectal > Retention enema: 3 g per 100 mL

Indications

[Crohn disease site](#) [Ulcerative colitis](#)



Sumatriptan [General information](#)

Section

Medicines for cluster headache

- Parenteral > General injections > SC: 6 mg per 0.5 mL in pre-filled pen; 6 mg per 0.5 mL in pre-filled syringe

Indications

[Trigeminal autonomic cephalalgias](#)

Section

Medicines for acute migraine attacks

- Oral > Solid > tablet: 50 mg

Indications

[Migraine](#)



Sunscreen, broad-spectrum [General information](#)

Section

Dermatological medicines

- Topical cream, lotion, gel, ointment, spray with sun protection factor ≥ 50 .

Indications

[Xeroderma pigmentosum](#)

Section

Dermatological medicines > Sunscreens

- Topical:
- Therapeutic broad-spectrum sunscreens should contain proven active ingredients in appropriate amounts to absorb or filter UVA and UVB radiation, and have a high sun protection factor (SPF).

Indications

[Albinism or other specified genetically-determined hypomelanotic disorders](#)

Suramin sodium [General information](#)

Section

Antifilarials

- Parenteral > General injections > IV: 1 g in vial

Indications

[Filariasis](#)

Section

Medicines for the treatment of 1st stage African trypanosomiasis

- Parenteral > General injections > IV: 1 g in vial

Indications

[Rhodesiense trypanosomiasis](#)

Suxamethonium [General information](#)

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

- Parenteral > General injections > IV: 50 mg per mL in 2 mL ampoule (chloride)

Indications

[Muscle relaxants](#)

Tacalcitol [General information](#)

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to [calcipotriol](#) for [Psoriasis of unspecified type](#)

Tacrolimus [General information](#)

Section

Immunomodulators for non-malignant disease

- Parenteral > General injections > IV: 5 mg per mL in 1 mL vial
- Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension
- Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)

Indications

[Failure or rejection of transplanted organs or tissues](#)

Tamoxifen [General information](#)

Section

Hormones and antihormones

- Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)

Indications

[Other specified malignant neoplasms of breast](#) [Malignant neoplasms of breast](#)

Tedizolid [General information](#)

Section

Reserve group antibiotics

Indications

Therapeutic equivalent to [linezolid](#) for [Methicillin resistant Staphylococcus aureus](#) Therapeutic equivalent to [linezolid](#) for [Vancomycin resistant Staphylococcus aureus](#) Therapeutic equivalent to [linezolid](#) for [Vancomycin resistant Enterococcus](#)

Telmisartan + amlodipine [General information](#)

Section

Antihypertensive medicines

- Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg

Indications

[Essential hypertension](#)



Telmisartan + hydrochlorothiazide [General information](#)

Section

Antihypertensive medicines

- Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg

Indications

[Essential hypertension](#)



Temozolomide [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 100 mg in vial powder for injection
- Oral > Solid > capsule: 5 mg; 20 mg; 100 mg; 140 mg; 180 mg; 250 mg

Indications

[Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Other specified gliomas of brain](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Neuroblastoma, NOS](#)



Tenofovir alafenamide [General information](#)

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 25 mg

Indications

[Chronic hepatitis B](#)



Tenofovir disoproxil fumarate [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#) [Contact with or exposure to human immunodeficiency virus](#)

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Indications

[Chronic hepatitis B](#)



Terbinafine [General information](#)

Section

Dermatological medicines > Antifungal medicines

- Local > Topical > Cream: 1% terbinafine hydrochloride
- Local > Topical > Ointment: 1% terbinafine hydrochloride

Indications

[Fungal infection of the skin](#)



Terbutaline [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [salbutamol](#) for [Chronic obstructive pulmonary disease](#) Therapeutic equivalent to [salbutamol](#) for [Asthma](#)



Terizidone [General information](#)

Section

Antituberculosis medicines

- Oral > Solid > capsule: 250 mg

Indications

Therapeutic equivalent to [cycloserine](#) for [Multi-drug resistant Mycobacterium tuberculosis](#)

Testosterone [General information](#)

Section

Androgens

- Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)

Indications

[Testicular dysfunction or testosterone-related disorders](#)

Tetanus antitoxin [General information](#)

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

- Parenteral > General injections > IM: 50000 IU in vial

Indications

[Tetanus](#)

Tetanus vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against tetanus alone](#)

Tetracaine [General information](#)

Section

Ophthalmological preparations > Local anaesthetics

- Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride)

Indications

[Local anaesthetics](#)

Tetracycline [General information](#)

Section

Access group antibiotics

- Oral > Solid: 250 mg (hydrochloride)

Indications

[Bacterial infection of unspecified site](#)

Section

Ophthalmological preparations > Anti-infective agents

- Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)

Indications

[Other specified conjunctivitis Infectious keratitis Trachoma Infectious blepharitis](#)

Thalidomide [General information](#)

Section

Immunomodulators

- Oral > Solid: 50 mg

Indications

[Plasma cell myeloma](#)

Thiamine [General information](#)

Section

Vitamins and minerals

- Parenteral > General injections > IV: 50 mg per mL in ampoule or vial (hydrochloride)
- Oral > Solid > tablet: 50 mg (hydrochloride)

Indications

[Vitamin B1 deficiency](#)

Thiopental [General information](#)

Section

General anaesthetics and oxygen > Injectable medicines

Indications

Therapeutic equivalent to [propofol](#) for [Anaesthetics and therapeutic gases](#)

Ticagrelor [General information](#)

Section

Anti-platelet medicines

- Oral > Solid > tablet: 60 mg; 90 mg

Indications

[Acute ischaemic heart disease](#) [Presence of coronary angioplasty implant or graft](#)

Tick-borne encephalitis vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against arthropod-borne viral encephalitis](#)

Tigecycline [General information](#)

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 50 mg in vial powder for injection

Indications

[Other specified bacterial diseases](#)

Timolol [General information](#)

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

- Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)

Indications

[Ocular hypertension](#) [Primary open-angle glaucoma](#)

Tinidazole [General information](#)

Section

Antiamoebic and anti giardiasis medicines

Indications

Therapeutic equivalent to [metronidazole](#) for [Amoebiasis](#)

Tiotropium bromide [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

- Respiratory > Inhalation > powder: 18 µg in capsule
- Respiratory > Inhalation > solution: 1.25 µg per actuation in soft mist inhaler; 2.5 µg per actuation in soft mist inhaler

Indications

[Chronic obstructive pulmonary disease](#)

Tirzepatide [General information](#)

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for [Obesity](#) Therapeutic equivalent to [semaglutide](#) for [Type 2 diabetes mellitus](#)

Tisagenlecleucel [General information](#)

Section

Antineoplastics and supportive medicines

Indications

Therapeutic equivalent to [axicabtagene ciloleucel](#) for [Diffuse large B-cell lymphomas](#)

Tislelizumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 100 mg per 10 mL
- Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion
- Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion

Indications

[Malignant neoplasms of urinary tract Hodgkin lymphoma Other specified malignant neoplasms of bronchus or lung Squamous cell carcinoma of oesophagus](#)

Tobramycin [General information](#)

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to [gentamicin](#) for [Other specified conjunctivitis](#) Therapeutic equivalent to [gentamicin](#) for [Infectious blepharitis](#)

Tocilizumab [General information](#)

Section

Medicines for juvenile joint diseases

- Parenteral > General injections > IV: 80 mg per 4 mL in vial; 200 mg per 10 mL in vial; 400 mg per 20 mL in vial
- Parenteral > General injections > SC: 162 mg per 0.9 mL in pre-filled syringe

Indications

[Juvenile systemic arthritis](#)

Tolbutamide [General information](#)

Section

Hypoglycaemic agents

- Oral > Solid: 500 mg

Indications

[Type 2 diabetes mellitus](#)

Torasemide [General information](#)

Section

Medicines used in heart failure

Indications

Therapeutic equivalent to [furosemide](#) for [Heart failure](#)

Section

Diuretics

Indications

Therapeutic equivalent to [furosemide](#) for [Anuria or oliguria](#) Therapeutic equivalent to [furosemide](#) for [Oedema](#)

Toripalimab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 240 mg per 6 mL in vial

Indications

[Malignant neoplasms of nasopharynx Squamous cell carcinoma of oesophagus](#)

Tramadol [General information](#)

Section

Opioid analgesics

- Oral > Liquid: 100 mg per mL (hydrochloride)
- Oral > Solid: 50 mg (hydrochloride) immediate release; 50 mg (hydrochloride) controlled release; 100 mg (hydrochloride) controlled release; 150 mg (hydrochloride) controlled release; 200 mg (hydrochloride) controlled release; 300 mg (hydrochloride) controlled release; 400 mg (hydrochloride) controlled release
- Parenteral > General injections > unspecified: 50 mg per mL in 2 mL ampoule (hydrochloride)

Indications

[Chronic cancer pain](#)



Trametinib [General information](#)

Section

Targeted therapies

- Oral > Solid: 0.5 mg; 2 mg

Indications

[Other specified melanoma of skin](#)



Tranexamic acid [General information](#)

Section

Medicines affecting coagulation

- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Indications

[Haemorrhage, not elsewhere classified](#)

Section

Other medicines administered to the mother

- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Indications

[Postpartum haemorrhage](#)



Trastuzumab [General information](#)

Section

Targeted therapies

- Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection

Indications

[Carcinoma of breast, specialised type](#)



Trastuzumab emtansine [General information](#)

Section

Targeted therapies

- Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection

Indications

[Carcinoma of breast, specialised type](#)



Tremelimumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion

Indications

[Hepatocellular carcinoma of liver](#) [Other specified malignant neoplasms of bronchus or lung](#)



Triamcinolone hexacetonide [General information](#)

Section

Medicines for juvenile joint diseases

- Parenteral > Locoregional injections > Intra-articular: 20 mg per mL in vial

Indications

[Juvenile idiopathic arthritis](#)



Triclabendazole [General information](#)

Section

Antischistosomes and other antitrematode medicines

- Oral > Solid > tablet: 250 mg (scored)

Indications

[Paragonimiasis Fascioliasis](#)



Trihexyphenidyl [General information](#)

Section

Medicines for central nervous system disorders

- Oral > Solid: 2 mg (hydrochloride); 5 mg (hydrochloride)

Indications

[Parkinson disease](#)

Section

Medicines for parkinsonism

Indications

Therapeutic equivalent to [biperiden](#) for [Parkinson disease](#)



Trimethoprim [General information](#)

Section

Access group antibiotics

- Oral > Liquid: 50 mg per mL
- Oral > Solid: 100 mg; 200 mg

Indications

First choice

[Infectious cystitis](#)



Triptorelin [General information](#)

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [leuprorelin](#) for [Malignant neoplasms of breast](#) Therapeutic equivalent to [leuprorelin](#) for [Malignant neoplasms of prostate](#)



Tropicamide [General information](#)

Section

Diagnostic agents > Ophthalmic medicines

- Local > Ophthalmological > Solution (eye drops): 0.5%

Indications

[Cycloplegic drug](#)



Tropisetron [General information](#)

Section

Medicines for other common symptoms in palliative care

Indications

Therapeutic equivalent to [ondansetron](#) for [Palliative care](#)

Section

Antiemetic medicines

Indications

Therapeutic equivalent to [ondansetron](#) for [Nausea or vomiting](#)



Tuberculin, purified protein derivative [General information](#)

Section

Immunologicals > Diagnostic agents

- Parenteral > Locoregional injections > Intradermal:

Indications

[Mycobacterial diseases](#)

Tubocurarine [General information](#)

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

- Parenteral > General injections > IV: 10 mg per mL in 1.5 mL ampoule (tubocurarine chloride)

Indications

[Muscle relaxants](#)

Typhoid vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against typhoid-paratyphoid alone](#)

Ulipristal [General information](#)

Section

Oral hormonal contraceptives

- Oral > Solid: 30 mg tablet (ulipristal acetate)

Indications

[Contact with health services for postcoital contraception](#)

Umeclidinium [General information](#)

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [tiotropium bromide](#) for [Chronic obstructive pulmonary disease](#)

Urea [General information](#)

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Local > Topical > Cream: 10%; 5%
- Local > Topical > Ointment: 10%; 5%

Indications

[Xerosis cutis or asteatosis](#)

Section

Dermatological medicines > Moisturizers

- Local > Topical > Cream: 5 per %

Indications

[Atopic eczema](#)

Ustekinumab [General information](#)

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Parenteral > General injections > SC: 45 mg per 0.5 mL in vial; 45 mg per 0.5 mL in pre-filled syringe; 45 mg per 0.5 mL in pre-filled pen; 90 mg per mL in pre-filled syringe; 90 mg per mL in pre-filled pen

Indications

[Psoriasis of unspecified type](#)

Valaciclovir [General information](#)

Section

Medicines for viral central nervous system infections

Indications

Therapeutic equivalent to [aciclovir](#) for [Herpes simplex infections](#) Therapeutic equivalent to [aciclovir](#) for [Zoster](#)

Therapeutic equivalent to [aciclovir](#) for [Varicella](#)

Valganciclovir [General information](#)

Section

Other antivirals

- Oral > Liquid: 50 mg per mL (as hydrochloride) powder for oral solution
- Oral > Solid > tablet: 450 mg (as hydrochloride)

Indications

[Cytomegaloviral retinitis](#)



Valproic acid (sodium valproate) [General information](#)

Section

Antiseizure medicines

- Oral > Liquid: 200 mg per 5 mL
- Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable)
- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 3 mL ampoule

Indications

[Epilepsy or seizures Status epilepticus](#)

Section

Medicines for bipolar disorders

- Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)

Indications

[Bipolar or related disorders](#)



Valsartan + amlodipine + hydrochlorothiazide [General information](#)

Section

Antihypertensive medicines

- Oral > Solid > dosage form: 160 mg + 5 mg + 12.5 mg; 160 mg + 5 mg + 25 mg; 160 mg + 10 mg + 12.5 mg; 160 mg + 10 mg + 25 mg; 320 mg + 10 mg + 25 mg

Indications

[Essential hypertension](#)



Vancomycin [General information](#)

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
- Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

Indications

First choice

[Necrotising fasciitis](#) co-prescribed with [ceftazidime](#) [Endophthalmitis](#) co-prescribed with [ceftriaxone](#) [Endophthalmitis](#)

Second choice

[Intestinal infections due to Clostridioides difficile](#) [Neutropenia \(high-risk\)](#)

Other indications

[Methicillin resistant Staphylococcus aureus](#)



Varenicline [General information](#)

Section

Medicines for nicotine use disorders

- Oral > Solid: 0.5 mg; 1 mg

Indications

[Nicotine dependence](#)



Varicella vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against certain single viral diseases](#)



Vecuronium [General information](#)

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

- Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)

Indications

[Muscle relaxants](#)



Vemurafenib [General information](#)

Section

Targeted therapies

Indications

Therapeutic equivalent to [dabrafenib](#) for [Other specified melanoma of skin](#)



Verapamil [General information](#)

Section

Antiarrhythmic medicines

- Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule (hydrochloride)
- Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)

Indications

[Supraventricular tachyarrhythmia](#)

Section

Antianginal medicines

- Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)

Indications

[Angina pectoris](#)

Section

Medicines for cluster headache

- Oral > Solid > tablet: 120 mg (hydrochloride) (immediate-release); 40 mg (hydrochloride) (immediate-release); 80 mg (hydrochloride) (immediate-release); 120 mg (hydrochloride) (extended-release); 180 mg (hydrochloride) (extended-release); 240 mg (hydrochloride) (extended-release)

Indications

[Trigeminal autonomic cephalgias](#)



Vinblastine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Other specified gliomas of brain](#) [Hodgkin lymphoma](#) [Other specified malignant neoplasms of the ovary](#) [Germ cell tumour of testis](#) [Kaposi sarcoma of unspecified primary site](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#) [Langerhans cell histiocytosis](#)



Vincristine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
- Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Other specified gliomas of brain](#) [Follicular lymphoma](#) [Malignant trophoblastic neoplasms of placenta](#) [Diffuse large B-cell lymphoma, not otherwise specified](#) [Kaposi sarcoma of unspecified primary site](#) [Rhabdomyosarcoma primary site](#) [Hodgkin lymphoma](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Lymphoid leukaemia, not elsewhere classified](#) [Retinoblastoma](#) [Langerhans cell histiocytosis](#)



Vinorelbine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
- Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
- Oral > Solid > capsule: 20 mg; 30 mg; 80 mg

Indications

[Other specified malignant neoplasms of bronchus or lung](#) [Other specified malignant neoplasms of breast](#)
[Rhabdomyosarcoma primary site](#)

Voriconazole [General information](#)

Section

Antifungal medicines

- Parenteral > General injections > IV: 200 mg in vial powder for injection
- Oral > Liquid: 40 mg per mL powder for oral liquid
- Oral > Solid: 50 mg tablet; 200 mg tablet

Indications

[Invasive aspergillosis](#) [Chronic pulmonary aspergillosis](#)

Warfarin [General information](#)

Section

Medicines affecting coagulation

- Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)
- Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)

Indications

[Other specified diseases of arteries or arterioles](#) [Venous thromboembolism](#) [Cerebral ischaemic stroke due to embolic occlusion](#) [Atrial fibrillation](#)

Water for injection [General information](#)

Section

Solutions correcting water, electrolyte and acid-base disturbances > Miscellaneous

- Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule

Indications

[Unspecified appropriateness of dosing or administration without injury or harm](#)

Whole blood [General information](#)

Section

Blood and blood components

- Parenteral > General injections > IV:

Indications

[Blood transfusion without reported diagnosis](#)

Yellow fever vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against certain single viral diseases](#)

Zanubrutinib [General information](#)

Section

Targeted therapies

- Oral > Solid: 80 mg
- Oral > Solid > capsule: 80 mg

Indications

[Mantle cell lymphoma](#) [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#) Therapeutic equivalent to [ibrutinib](#) for [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#)

Zidovudine [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion
- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid > tablet: 300 mg
- Oral > Solid > capsule: 250 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Zinc sulfate [General information](#)

Section

Medicines for diarrhoea

- Oral > Solid > dispersible tablet: 20 mg (scored)

Indications

[Diarrhoea](#)



Zoledronic acid [General information](#)

Section

Supportive medicines

- Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

Indications

[Malignant neoplasm metastasis in bone or bone marrow](#)

Section

Medicines for endocrine disorders

- Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

Indications

[Osteogenesis imperfecta](#)



Zuclopenthixol decanoate [General information](#)

Section

Medicines for psychotic disorders

Indications

Therapeutic equivalent to [fluphenazine](#) for [Schizophrenia or other primary psychotic disorders](#)